

L Jeffrey Medeiros

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/754983/publications.pdf](https://exaly.com/author-pdf/754983/publications.pdf)

Version: 2024-02-01

1,027
papers

43,968
citations

2192

96
h-index

6173

153
g-index

1083
all docs

1083
docs citations

1083
times ranked

29445
citing authors

#	ARTICLE	IF	CITATIONS
1	Adapted ST analysis during labor: relative versus absolute ST events, a case-control study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2024, 35, 7375-7380.	1.8	0
2	Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy. <i>Pathology</i> , 2024, 56, 367-373.	0.7	1
3	Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. <i>Blood Cancer Journal</i> , 2024, 14, .	6.4	1
4	Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissues: B-cell Neoplasms. <i>Modern Pathology</i> , 2024, 37, 100441.	5.8	0
5	Low-grade histiocytic sarcoma with aggressive clinical behaviour: an unusual case with novel genetic mutations identified by whole genome sequencing. <i>Pathology</i> , 2024, , .	0.7	0
6	Kikuchi disease with an exuberant proliferation of large Tâ€œcells: a study of 25 cases that can mimic <sc>Tâ€œCell</sc> lymphoma. <i>Histopathology</i> , 2023, 82, 340-353.	3.1	5
7	3q26.2/MECOM Rearrangements by Pericentric Inv(3): Diagnostic Challenges and Clinicopathologic Features. <i>Cancers</i> , 2023, 15, 458.	3.9	4
8	The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation. <i>Cancers</i> , 2023, 15, 198.	3.9	4
9	Blastoid B-Cell Neoplasms: Diagnostic Challenges and Solutions. <i>Cancers</i> , 2023, 15, 848.	3.9	2
10	Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. <i>Pathology</i> , 2023, 55, 514-524.	0.7	3
11	High-grade B-cell lymphoma, not otherwise specified: aâ€œmulti-institutional retrospective study. <i>Blood Advances</i> , 2023, 7, 6381-6394.	5.5	4
12	T-prolymphocytic leukemia: TCL1 or MTCP1 rearrangement is not mandatory to establish diagnosis. <i>Leukemia</i> , 2023, 37, 1919-1921.	7.5	5
13	TdT-positive high-grade B-cell lymphoma with BCOR and IDH1 mutations. <i>Pathology</i> , 2023, , .	0.7	0
14	Origin of the terms â€œwater potâ€œ™ and â€œstarry skyâ€œ™ in Burkitt lymphoma. <i>Pathology</i> , 2023, , .	0.7	0
15	Introduction to the Fifth Edition of the World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. <i>Modern Pathology</i> , 2023, 36, 100330.	5.8	3
16	Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. <i>Blood Advances</i> , 2023, 7, 7393-7401.	5.5	2
17	Recurrent Somatic Copy Number Alterations and Their Association with Oncogene Expression Levels in High-Grade Ovarian Serous Carcinoma. <i>Life</i> , 2023, 13, 2192.	2.5	1
18	Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells. <i>Cancers</i> , 2023, 15, 5690.	3.9	0

#	ARTICLE	IF	CITATIONS
19	Optical Genome Mapping Helps to Identify BCR::JAK2 Rearrangement Arising from Cryptic Complex Chromosomal Aberrations: A Case Report and Literature Review. <i>Genes</i> , 2023, 14, 2188.	2.4	1
20	Artificial intelligence strategy integrating morphologic and architectural biomarkers provides robust diagnostic accuracy for disease progression in chronic lymphocytic leukemia. <i>Journal of Pathology</i> , 2022, 256, 4-14.	4.5	22
21	Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. <i>Modern Pathology</i> , 2022, 35, 306-318.	5.8	19
22	Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge. <i>Modern Pathology</i> , 2022, 35, 419-426.	5.8	17
23	Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2022, 35, 412-418.	5.8	4
24	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 202-212.	5.3	40
25	Clinicopathological features of syncytial variant nodular sclerosis Hodgkin lymphoma. <i>Human Pathology</i> , 2022, 119, 105-113.	2.4	3
26	Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 370-376.	2.5	8
27	Unexpected myeloid sarcoma of the tonsil in a patient without a history of hematological neoplasm. <i>Blood</i> , 2022, 139, 148-148.	1.4	1
28	Artificial intelligence-assisted mapping of proliferation centers allows the distinction of accelerated phase from large cell transformation in chronic lymphocytic leukemia. <i>Modern Pathology</i> , 2022, 35, 1121-1125.	5.8	7
29	LncRNA GAL promotes colorectal cancer liver metastasis through stabilizing GLUT1. <i>Oncogene</i> , 2022, 41, 1882-1894.	5.9	31
30	3â€²CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant. <i>Annals of Hematology</i> , 2022, 101, 847-854.	1.9	2
31	Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not B-Cell Non-Hodgkin Lymphomas. <i>Cancers</i> , 2022, 14, 1186.	3.9	4
32	Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2022, 116, 106827.	1.1	1
33	Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. <i>Leukemia</i> , 2022, 36, 1343-1350.	7.5	27
34	Magnetisation switching dynamics induced by combination of spin transfer torque and spin orbit torque. <i>Scientific Reports</i> , 2022, 12, 3380.	3.5	18
35	Understanding signatures of positive natural selection in human zinc transporter genes. <i>Scientific Reports</i> , 2022, 12, 4320.	3.5	2
36	Population Source of Third-Generation Oriental Armyworm in Jilin, China, Determined by Entomology Radar, Trajectory Analysis, and Mitochondrial COI Sequences. <i>Environmental Entomology</i> , 2022, 51, 621-632.	1.6	2

#	ARTICLE	IF	CITATIONS
37	<i>TP53</i> copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. <i>Blood</i> , 2022, 140, 58-72.	1.4	57
38	Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 3472-3479.	5.5	16
39	From the archives of MD Anderson Cancer Center: Intravascular large B-cell lymphoma with numerous circulating lymphoma cells. <i>Annals of Diagnostic Pathology</i> , 2022, 58, 151934.	1.4	1
40	Primary mediastinal germ cell tumor and clonally related and unique hematologic neoplasms with <i>i(12p)</i> and <i>TP53</i> mutation: A report of two cases. <i>Annals of Diagnostic Pathology</i> , 2022, 59, 151951.	1.4	1
41	Chronic Lymphocytic Leukemia Progression Diagnosis with Intrinsic Cellular Patterns via Unsupervised Clustering. <i>Cancers</i> , 2022, 14, 2398.	3.9	8
42	Effects of land use change on ecosystem services in the China–Mongolia–Russia economic corridor. <i>Journal of Cleaner Production</i> , 2022, 360, 132175.	9.5	52
43	Optimization of Lipopeptide Biosurfactant Production by <i>Salibacterium</i> sp. 4CTb in Batch Stirred-Tank Bioreactors. <i>Microorganisms</i> , 2022, 10, 983.	3.7	3
44	Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. <i>Modern Pathology</i> , 2022, 35, 1212-1219.	5.8	10
45	MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome. <i>Cancers</i> , 2022, 14, 2433.	3.9	8
46	Nodular Lymphocyte–predominant Hodgkin Lymphoma With Nodular Sclerosis. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1291-1297.	4.0	2
47	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> , 2022, 36, 1720-1748.	7.5	1,398
48	Expression pattern and diagnostic utility of <i>BCL11B</i> in mature T- and NK-cell neoplasms. <i>Pathology</i> , 2022, , .	0.7	0
49	Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2022, 14, 3375.	3.9	10
50	PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas. <i>Biomedicines</i> , 2022, 10, 1587.	3.3	9
51	Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods. <i>Cancers</i> , 2022, 14, 4550.	3.9	9
52	Intracranial inflammation-rich germinoma mimicking haematological neoplasms: a diagnostic pitfall. <i>Pathology</i> , 2022, , .	0.7	0
53	MET Amplification (MET/CEP7 Ratio ≥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naïve Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e512-e518.	2.7	11
54	CD45-negative follicular lymphoma: A rare diagnostic pitfall of a common entity. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 406-408.	1.7	2

#	ARTICLE	IF	CITATIONS
55	<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma. <i>Haematologica</i> , 2021, 106, 1381-1389.	3.5	26
56	Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. <i>Haematologica</i> , 2021, 106, 1047-1055.	3.5	43
57	Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 352-360.	1.7	11
58	Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma. <i>Haematologica</i> , 2021, 106, 1714-1724.	3.5	35
59	Langerhans cell sarcoma involving skin and showing epidermotropism: A comprehensive review. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 547-557.	1.5	3
60	Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. <i>Cancer Cytopathology</i> , 2021, 129, 374-382.	2.6	25
61	Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/SÜazary syndrome than quantification of <sc>CD26</sc> or <sc>CD7</sc> <sc>CD4</sc>+ Tâcells. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 183-191.	1.7	16
62	Higher infiltration of intratumoral CD25+ FOXP3+ lymphocytes correlates with a favorable prognosis in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 76-85.	1.4	10
63	Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcome. <i>Experimental and Molecular Pathology</i> , 2021, 118, 104572.	2.3	3
64	Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience. <i>Modern Pathology</i> , 2021, 34, 854-861.	5.8	10
65	From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later. <i>Annals of Diagnostic Pathology</i> , 2021, 50, 151649.	1.4	1
66	MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma. <i>Human Pathology</i> , 2021, 108, 22-31.	2.4	6
67	Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. <i>Modern Pathology</i> , 2021, 34, 300-313.	5.8	7
68	CD123 Expression in Philadelphia Chromosome-like B Acute Lymphoblastic Leukemia/Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e317-e320.	0.4	5
69	Changes in subjective measures of appetite during 6 months of alternate day fasting with a low carbohydrate diet. <i>Clinical Nutrition ESPEN</i> , 2021, 41, 417-422.	1.2	7
70	The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. <i>Modern Pathology</i> , 2021, 34, 327-335.	5.8	8
71	Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1405-1412.	2.6	6
72	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with <i>NPM1</i>-mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 1054-1063.	2.8	32

#	ARTICLE	IF	CITATIONS
73	Epstein-Barr virus latent membrane protein-1 upregulates autophagy and promotes viability in Hodgkin lymphoma: Implications for targeted therapy. <i>Cancer Science</i> , 2021, 112, 1589-1602.	4.0	10
74	Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. <i>Modern Pathology</i> , 2021, 34, 1143-1152.	5.8	12
75	Clinicopathologic Features of Myelodysplastic Syndromes Involving Lymph Nodes. <i>American Journal of Surgical Pathology</i> , 2021, Publish Ahead of Print, 930-938.	4.0	0
76	Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2021, 193, 488-496.	2.8	13
77	Primary Effusion Lymphoma: A Clinicopathological Study of 70 Cases. <i>Cancers</i> , 2021, 13, 878.	3.9	30
78	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. <i>Blood Cancer Journal</i> , 2021, 11, 52.	6.4	6
79	Follicular dendritic cell sarcoma in the differential diagnosis of GATA3 positive tumors: A case report. <i>Human Pathology: Case Reports</i> , 2021, 23, 200473.	0.2	0
80	Syncytial variant of nodular sclerosis Hodgkin lymphoma: an under-emphasized variant. <i>Human Pathology</i> , 2021, 117, 115-125.	2.4	8
81	Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis - Chronic Myelomonocytic Leukemia and Beyond. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 286-303.	2.4	0
82	Myeloid/lymphoid neoplasms with FLT3 rearrangement. <i>Modern Pathology</i> , 2021, 34, 1673-1685.	5.8	24
83	Particle Trapping in Arbitrary Trajectories Using First-Order Bessel-Like Acoustic Beams. <i>Physical Review Applied</i> , 2021, 15, .	3.9	25
84	From the archives of MD Anderson Cancer Center: A case of concurrent follicular lymphoma and Langerhans cell sarcoma with a review of the literature. <i>Annals of Diagnostic Pathology</i> , 2021, 52, 151720.	1.4	2
85	Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease. <i>Modern Pathology</i> , 2021, 34, 2148-2153.	5.8	14
86	Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy. <i>Cold Spring Harbor Molecular Case Studies</i> , 2021, 7, a006084.	1.4	4
87	Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. <i>Cancer</i> , 2021, 127, 3552-3565.	4.1	20
88	Future of Education or Present Reality?. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1350-1354.	2.6	4
89	Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon. <i>Leukemia and Lymphoma</i> , 2021, 62, 3296-3299.	1.4	4
90	Predicting therapeutic alliance with client characteristics and expectations in Hong Kong. <i>Asia Pacific Journal of Counselling and Psychotherapy</i> , 2021, 12, 111-126.	0.3	0

#	ARTICLE	IF	CITATIONS
91	Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. <i>Modern Pathology</i> , 2021, 34, 2154-2167.	5.8	29
92	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. <i>Modern Pathology</i> , 2021, 34, 2183-2191.	5.8	8
93	From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia. <i>Annals of Diagnostic Pathology</i> , 2021, 53, 151767.	1.4	3
94	Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. <i>Clinical Cancer Research</i> , 2021, 27, 5847-5856.	7.3	4
95	Hematogones with light chain restriction: A potential diagnostic pitfall when using flow cytometry analysis to assess bone marrow specimens. <i>Leukemia Research</i> , 2021, 111, 106704.	1.1	2
96	Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2021, 108, 106616.	1.1	2
97	B-prolymphocytic leukemia: Is it time to retire this entity?. <i>Annals of Diagnostic Pathology</i> , 2021, 54, 151790.	1.4	9
98	Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation - First case series from a single institution. <i>Leukemia Research</i> , 2021, 111, 106685.	1.1	2
99	The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1361-1369.	1.4	7
100	Disseminated ALK-positive histiocytosis with KIF5B-ALK fusion in an adult. <i>Leukemia and Lymphoma</i> , 2021, 62, 1234-1238.	1.4	14
101	MDMX/MDM4 is highly expressed and contributes to cell growth and survival in anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1563-1573.	1.4	3
102	Postchemotherapy Histiocyte-rich Pseudotumor Mimicking Residual Lymphoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 160-168.	4.0	5
103	Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases. <i>Human Pathology</i> , 2021, 118, 60-68.	2.4	4
104	CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. <i>Cancers</i> , 2021, 13, 5354.	3.9	4
105	High-Throughput Characterization of Cytogenomic Heterogeneity of MDS Using High-Resolution Optical Genome Mapping. <i>Blood</i> , 2021, 138, 105-105.	1.4	1
106	Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. <i>Blood</i> , 2021, 138, 4536-4536.	1.4	0
107	Machine Learning Pipeline with Feature Engineering Provides Robust Diagnostic Predictions in Chronic Lymphocytic Leukemia, Accelerated and Transformed Phases. <i>Blood</i> , 2021, 138, 3738-3738.	1.4	0
108	Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML. <i>Blood</i> , 2021, 138, 607-607.	1.4	2

#	ARTICLE	IF	CITATIONS
109	Artificial Intelligence-Assisted Mapping of Proliferation Centers in Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Identifies Patterns That Reliably Distinguish Accelerated Phase and Large Cell Transformation. <i>Blood</i> , 2021, 138, 1558-1558.	1.4	1
110	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. <i>Modern Pathology</i> , 2021, , .	5.8	10
111	Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. <i>Blood</i> , 2021, 138, 1448-1448.	1.4	0
112	The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis. <i>Cancers</i> , 2021, 13, 6316.	3.9	3
113	Opposite subgenual cingulate cortical functional connectivity and metabolic activity patterns in refractory melancholic major depression. <i>Brain Imaging and Behavior</i> , 2020, 14, 426-435.	2.2	4
114	Lowâ€Grade Myelodysplastic Syndromes with Preserved CD34+ Bâ€Cell Precursors (CD34+ Hematogones). <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 36-42.	1.7	12
115	KSHV/HHV8-positive large B-cell lymphomas and associated diseases: a heterogeneous group of lymphoproliferative processes with significant clinicopathological overlap. <i>Modern Pathology</i> , 2020, 33, 18-28.	5.8	42
116	PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2020, 33, 324-333.	5.8	33
117	Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. <i>Leukemia and Lymphoma</i> , 2020, 61, 171-175.	1.4	15
118	A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2020, 33, 367-379.	5.8	30
119	Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. <i>Pathology</i> , 2020, 52, 154-165.	0.7	63
120	Outcomes in patients with aggressive Bâ€cell nonâ€Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020, 126, 293-303.	4.1	22
121	Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update. <i>Modern Pathology</i> , 2020, 33, 1104-1121.	5.8	20
122	Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors. <i>Cancer Genetics</i> , 2020, 241, 57-60.	0.4	4
123	Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for <i>RHOA</i> G17V mutated subtype. <i>Leukemia and Lymphoma</i> , 2020, 61, 1108-1118.	1.4	6
124	Immunopathology of Kikuchiâ€Fujimoto disease: A reappraisal using novel immunohistochemistry markers. <i>Histopathology</i> , 2020, 77, 262-274.	3.1	15
125	Updated direct costs of medical care for HIVâ€infected patients within a regional population from 2006 to 2017. <i>HIV Medicine</i> , 2020, 21, 289-298.	2.3	10
126	Myeloid neoplasm with eosinophilia and BCR-JAK2/t(9;22)(p24;q11.2) morphologically mimicking chronic myeloid leukemia. <i>Annals of Diagnostic Pathology</i> , 2020, 44, 151405.	1.4	6

#	ARTICLE	IF	CITATIONS
127	Diffuse large B-cell lymphoma variants: an update. <i>Pathology</i> , 2020, 52, 53-67.	0.7	110
128	High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification. <i>Pathology</i> , 2020, 52, 68-77.	0.7	33
129	<i>RAS</i> and <i>TP53</i> can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. <i>Cancer Medicine</i> , 2020, 9, 849-858.	2.9	9
130	Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2020, 189, 313-317.	2.8	7
131	Lymphoma 2020: an update on recent advances in pathobiology and application to clinical practice. <i>Pathology</i> , 2020, 52, 1-5.	0.7	3
132	Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. <i>Leukemia and Lymphoma</i> , 2020, 61, 963-966.	1.4	3
133	Hydroa Vacciniforme-Like Lymphoproliferative Disorder With Progression to EBV+ Cytotoxic Peripheral T-Cell Lymphoma. <i>American Journal of Dermatopathology</i> , 2020, 42, 714-716.	0.7	2
134	Dietary supplementation of plant essential oil improves growth performance, intestinal morphology and health in weaned pigs. <i>Journal of Animal Physiology and Animal Nutrition</i> , 2020, 104, 579-589.	2.2	18
135	American Registry of Pathology Expert Opinions: Recommendations for the diagnostic workup of mature T cell neoplasms. <i>Annals of Diagnostic Pathology</i> , 2020, 49, 151623.	1.4	9
136	Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma. <i>Annals of Diagnostic Pathology</i> , 2020, 49, 151636.	1.4	4
137	Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. <i>Leukemia and Lymphoma</i> , 2020, 61, 3243-3246.	1.4	3
138	Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes. <i>Cancers</i> , 2020, 12, 1903.	3.9	0
139	Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2831-2838.	1.4	11
140	Clinical characteristics and outcomes of duodenal-type follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3266-3268.	1.4	5
141	Tumour-stage mycosis fungoides initially misdiagnosed as Langerhans cell histiocytosis. <i>Pathology</i> , 2020, 52, 593-596.	0.7	1
142	Climate change, air pollution, and allergic respiratory diseases: a call to action for health professionals. <i>Chinese Medical Journal</i> , 2020, 133, 1552-1560.	2.3	49
143	Social Media for Hematopathologists: Medical Practice Reinvented? #Hemepath. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 383-390.	2.4	10
144	KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma. <i>PLoS ONE</i> , 2020, 15, e0238477.	2.4	16

#	ARTICLE	IF	CITATIONS
145	HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients. <i>Aids</i> , 2020, 34, 1735-1743.	2.2	9
146	LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2020, 99, 2343-2349.	1.9	3
147	Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1235-1243.	4.0	28
148	Biopreservation and Biobanking's Mid-Year Update. <i>Biopreservation and Biobanking</i> , 2020, 18, 257-257.	1.1	0
149	MPN-402: Delayed Resolution of Bone Marrow Morphological Changes of Myelofibrosis Following Successful Stem Cell Transplant and Molecular Clearance of Disease: A Cautionary Tale. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S340-S341.	0.4	0
150	Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement. <i>Leukemia Research</i> , 2020, 99, 106460.	1.1	16
151	PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 372-381.	2.4	57
152	Chronic myeloid leukemia with insertion-derived BCR-ABL fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis. <i>Modern Pathology</i> , 2020, 33, 2035-2045.	5.8	3
153	T-cell clones of uncertain significance are highly prevalent and show close resemblance to T-cell large granular lymphocytic leukemia. Implications for laboratory diagnostics. <i>Modern Pathology</i> , 2020, 33, 2046-2057.	5.8	48
154	From the archives of MD Anderson Cancer Center: BCR-ABL1-like B acute lymphoblastic leukemia with IGH/EPOR fusion. <i>Annals of Diagnostic Pathology</i> , 2020, 46, 151514.	1.4	1
155	A suggested immunohistochemical algorithm for the classification of T-cell lymphomas involving lymph nodes. <i>Human Pathology</i> , 2020, 102, 104-116.	2.4	12
156	A Proposal for the Performance, Classification, and Reporting of Lymph Node Fine-Needle Aspiration Cytopathology: The Sydney System. <i>Acta Cytologica</i> , 2020, 64, 306-322.	1.2	61
157	High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia. <i>European Journal of Haematology</i> , 2020, 105, 449-459.	2.3	14
158	Epstein-Barr virus specific cytotoxic T lymphocytes for the treatment of severe Epstein-Barr virus mucocutaneous ulcer. <i>British Journal of Haematology</i> , 2020, 189, e33-e36.	2.8	3
159	Leukemic phase of Richter transformation: A mimic of acute myeloid leukemia that responded to ibrutinib monotherapy. <i>American Journal of Hematology</i> , 2020, 95, 1221-1223.	4.3	2
160	Classic Hodgkin lymphoma and Castleman disease: an entity appears to be emerging. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 437-444.	3.0	8
161	Reply to "PD-L1 expression in anaplastic large cell lymphoma". <i>Modern Pathology</i> , 2020, 33, 1234-1235.	5.8	0
162	Regulatory mechanisms of major depressive disorder risk variants. <i>Molecular Psychiatry</i> , 2020, 25, 1926-1945.	8.2	40

#	ARTICLE	IF	CITATIONS
163	iAMP21 in acute myeloid leukemia is associated with complex karyotype, TP53 mutation and dismal outcome. <i>Modern Pathology</i> , 2020, 33, 1389-1397.	5.8	10
164	T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid. <i>Leukemia</i> , 2020, 34, 2509-2512.	7.5	14
165	Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells. <i>Leukemia</i> , 2020, 34, 2460-2472.	7.5	9
166	Systematic use of fluorescence <i>in situ</i> hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms. <i>Histopathology</i> , 2020, 76, 1042-1054.	3.1	15
167	Formal and informal support and counselling for embryo donation and receipt: An Australian qualitative study. <i>Health and Social Care in the Community</i> , 2020, 28, 950-957.	1.7	3
168	MYC rearrangement and MYC/BCL2 double expression but not cell of origin predict prognosis in R-CHOP-treated diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 336-343.	2.3	15
169	Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. <i>BMC Cancer</i> , 2020, 20, 83.	2.6	11
170	Reconsideration of the first recognition of breast implant-associated anaplastic large cell lymphoma: A critical review of the literature. <i>Annals of Diagnostic Pathology</i> , 2020, 45, 151474.	1.4	18
171	CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma. <i>Human Pathology</i> , 2020, 98, 1-9.	2.4	10
172	Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia. <i>British Journal of Haematology</i> , 2020, 189, e207-e211.	2.8	1
173	B-cell lymphomas associated with breast implants: Report of three cases and review of the literature. <i>Annals of Diagnostic Pathology</i> , 2020, 46, 151512.	1.4	15
174	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	5.5	29
175	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. <i>Blood Advances</i> , 2020, 4, 1038-1050.	5.5	46
176	t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?. <i>Annals of Hematology</i> , 2020, 99, 487-500.	1.9	7
177	Posttransplant Lymphoproliferative Disorder Involving the Gastrointestinal Tract. <i>Journal of Digestive Endoscopy</i> , 2020, 11, 293-294.	0.2	1
178	ALK+ large B-cell lymphoma with aberrant expression of CD3. <i>Blood</i> , 2020, 136, 3086-3086.	1.4	3
179	Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. <i>Oncotarget</i> , 2020, 11, 600-618.	1.8	16
180	A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1300-1304.	5.4	4

#	ARTICLE	IF	CITATIONS
181	HHV8-Associated Lymphoproliferative Disorders. , 2020, , 439-446.		0
182	CT and 18F- FDG-PET-CT Findings in Secondary Adrenal Lymphoma with Pathologic Correlation. Academic Radiology, 2019, 26, e108-e114.	2.4	4
183	TRIM44 promotes quiescent multiple myeloma cell occupancy and survival in the osteoblastic niche via HIF-1 α stabilization. Leukemia, 2019, 33, 469-486.	7.5	35
184	Update on Lymphoma classification: The 2016 revised World Health Organization Classification of Hematopoietic and Lymphoid Neoplasms. Advances in Cell and Gene Therapy, 2019, 2, e57.	0.9	3
185	Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects. International Journal of Molecular Sciences, 2019, 20, 3939.	4.2	29
186	Targeting Cellular Metabolism Modulates Head and Neck Oncogenesis. International Journal of Molecular Sciences, 2019, 20, 3960.	4.2	26
187	Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models. International Journal of Molecular Sciences, 2019, 20, 3938.	4.2	14
188	7. Additional structural chromosomal abnormalities have a negative prognostic effect in patients with inv(16)/t(16;16) acute myeloid leukemia (AML). Cancer Genetics, 2019, 233-234, S3-S4.	0.4	1
189	Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Cancer Genetics, 2019, 238, 18-22.	0.4	12
190	The tumour microenvironment as an integrated framework to understand cancer biology. Cancer Letters, 2019, 461, 112-122.	7.4	62
191	Association of gene mutations with timeâ€œfirst treatment in 384 treatmentâ€œnaive chronic lymphocytic leukaemia patients. British Journal of Haematology, 2019, 187, 307-318.	2.8	29
192	Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens. Leukemia Research, 2019, 84, 106176.	1.1	7
193	Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Modern Pathology, 2019, 32, 1698-1707.	5.8	37
194	Philadelphia chromosomeâ€œnegative acute leukemia in patients with chronic myeloid leukemia. American Journal of Hematology, 2019, 94, E256-E259.	4.3	4
195	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. American Journal of Hematology, 2019, 94, 1066-1071.	4.3	18
196	Gaucher disease type 1 first recognized in an elderly patient with thrombocytopenia and lung adenocarcinoma. Clinical Case Reports (discontinued), 2019, 7, 1804-1805.	0.5	2
197	Epstein - Barr virus infection in de novo diffuse large B-cell lymphoma in Jordan and Turkey. Annals of Diagnostic Pathology, 2019, 43, 151406.	1.4	2
198	Reactive lymphadenopathy with concurrent idiopathic plasma cell variant Castleman disease, amyloid deposition and non-caseating granulomas. Pathology, 2019, 51, 762-764.	0.7	0

#	ARTICLE	IF	CITATIONS
199	Development and Application of Duplex Sequencing Strategy for Cell-Free DNA-Based Longitudinal Monitoring of Stage IV Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 994-1009.	3.0	5
200	Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies. <i>Data in Brief</i> , 2019, 24, 104025.	1.1	3
201	Data on synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel NURR1/NOT agonist potentially useful for the treatment of Parkinson's disease. <i>Data in Brief</i> , 2019, 27, 104057.	1.1	1
202	Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. <i>Leukemia Research</i> , 2019, 86, 106227.	1.1	2
203	Phenytoin-associated necrotising lymphadenitis mimicking Kikuchi disease. <i>Pathology</i> , 2019, 51, 650-653.	0.7	2
204	Unicentric Castleman disease, hyaline vascular variant, stromal rich, with increased plasma cells and a high level of serum IL-6: Raising the diagnostic and therapeutic issues. <i>Annals of Diagnostic Pathology</i> , 2019, 43, 151398.	1.4	1
205	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , 2019, 32, 741-754.	5.8	42
206	Genetic alterations and their clinical implications in DLBCL. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 634-652.	27.9	146
207	MALT lymphoma with IgM paraprotein and bone marrow involvement mimicking Waldenström macroglobulinaemia. <i>Pathology</i> , 2019, 51, 549-553.	0.7	1
208	Anal adenocarcinoma: Treatment outcomes and trends in a rare disease entity. <i>Cancer Medicine</i> , 2019, 8, 3855-3863.	2.9	19
209	Is hyperdiploidy a favorable cytogenetics in adults with B-lymphoblastic leukemia?. <i>Cancer Medicine</i> , 2019, 8, 4093-4099.	2.9	10
210	Scale-aware camera localization in 3D LiDAR maps with a monocular visual odometry. <i>Computer Animation and Virtual Worlds</i> , 2019, 30, e1879.	1.2	2
211	Emerging role of zinc finger protein A20 as a suppressor of hepatocellular carcinoma. <i>Journal of Cellular Physiology</i> , 2019, 234, 21479-21484.	4.2	9
212	The emergence of a <i>JAK2</i> V617F-mutated clone in myelodysplastic syndrome is associated with disease progression and features of myelofibrosis. <i>British Journal of Haematology</i> , 2019, 186, 396-396.	2.8	2
213	A longitudinal analysis of urological chronic pelvic pain syndrome flares in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. <i>BJU International</i> , 2019, 124, 522-531.	2.8	12
214	Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent <i>CD</i> 33 expression and <i>in vitro</i> response to targeted <i>CD</i> 33 therapy. <i>British Journal of Haematology</i> , 2019, 186, 538-548.	2.8	25
215	Polymorphisms in the promotor region of the <i>CRBN</i> gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. <i>British Journal of Haematology</i> , 2019, 186, 695-705.	2.8	7
216	Determinants of diagnostic delay in autoimmune atrophic gastritis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 167-175.	3.8	69

#	ARTICLE	IF	CITATIONS
217	TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. <i>Annals of Diagnostic Pathology</i> , 2019, 41, 38-42.	1.4	19
218	Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes. <i>Experimental and Molecular Pathology</i> , 2019, 108, 131-136.	2.3	2
219	CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis. <i>Human Pathology</i> , 2019, 89, 71-80.	2.4	24
220	The utility of CD83, fascin and CD23 in the differential diagnosis of primary mediastinal large B-cell lymphoma versus classic Hodgkin lymphoma. <i>Annals of Diagnostic Pathology</i> , 2019, 40, 72-76.	1.4	14
221	Radiographic manifestations of abnormal bone and mineral metabolism in end-stage renal disease. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 589-590.	0.5	1
222	Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. <i>Frontiers in Oncology</i> , 2019, 9, 107.	3.0	36
223	Relapsed B-acute lymphoblastic leukemia with aberrant myeloperoxidase expression following CAR T-cell therapy: A diagnostic challenge. <i>American Journal of Hematology</i> , 2019, 94, 1049-1051.	4.3	11
224	Biclonal presentation of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia. <i>Pathology</i> , 2019, 51, 340-343.	0.7	2
225	Unusual case of human herpesvirus 8-positive large B-cell lymphoma associated with Castleman disease. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 587-588.	0.5	1
226	Ce-Pr Mixed Oxide Catalysts with a Fibrous Morphology for Low-temperature PM Oxidation. <i>ChemCatChem</i> , 2019, 11, 2131-2141.	3.8	18
227	<i>DDX41</i> mutations in myeloid neoplasms are associated with male gender, <i>TP53</i> mutations and high-risk disease. <i>American Journal of Hematology</i> , 2019, 94, 757-766.	4.3	92
228	Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. <i>Cancer Genetics</i> , 2019, 233-234, 21-31.	0.4	13
229	Ring sideroblasts in chronic phase of polycythemia vera identifies a subset of patients with an increased risk of progression to blast phase. <i>Annals of Diagnostic Pathology</i> , 2019, 40, 45-48.	1.4	2
230	American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma. <i>Annals of Diagnostic Pathology</i> , 2019, 39, 105-110.	1.4	30
231	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 644-657.	3.3	119
232	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2019, 37, 2419-2427.	2.4	9
233	Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults. <i>Annals of Hematology</i> , 2019, 98, 1149-1157.	1.9	26
234	Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 817-825.	2.4	14

#	ARTICLE	IF	CITATIONS
235	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood Advances</i> , 2019, 3, 1356-1367.	5.5	12
236	TdT-positive high grade B-cell lymphoma transformed from grade 3B follicular lymphoma in an HIV-positive patient. <i>Pathology</i> , 2019, 51, 764-768.	0.7	4
237	Utility of Cyclin D1 in the Diagnostic Workup of Hematopoietic Neoplasms: What Can Cyclin D1 Do for Us?. <i>Advances in Anatomic Pathology</i> , 2019, 26, 281-291.	4.4	5
238	SOX11-negative Mantle Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 710-716.	4.0	23
239	Mantle Cell Lymphoma Involving Skin. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1421-1428.	4.0	15
240	Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1429-1437.	4.0	62
241	CD5-negative Mantle Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1052-1060.	4.0	26
242	Pioneers of Breast Implant-associated Anaplastic Large Cell Lymphoma: History from Case Report to Global Recognition. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 7S-14S.	1.6	31
243	Characteristics and Treatment of Advanced Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 41S-50S.	1.6	55
244	Assessment of penconazole exposure in winegrowers using urinary biomarkers. <i>Environmental Research</i> , 2019, 168, 54-61.	7.7	25
245	Persistent <i>IDH1/2</i> mutations in remission can predict relapse in patients with acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 305-311.	3.5	59
246	High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma. <i>Modern Pathology</i> , 2019, 32, 48-58.	5.8	48
247	Breast implant-associated anaplastic large cell lymphoma: a review. <i>Modern Pathology</i> , 2019, 32, 166-188.	5.8	106
248	<i>t(3;8)(q26.2;q24)</i> Often Leads to Mecom/MyC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and/or Disease Progression. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 343-351.	3.0	16
249	Ultra-Rapid Reporting of GENomic Targets (URGENTseq). <i>Journal of Molecular Diagnostics</i> , 2019, 21, 89-98.	3.0	25
250	Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis. <i>Human Pathology</i> , 2019, 85, 290-298.	2.4	20
251	Non-specific Liquid Fingerprinting in Monitoring the Hygiene and Authenticity of Milk. <i>Food Analytical Methods</i> , 2019, 12, 160-165.	2.6	1
252	Virtual discrete trial training for teacher trainees. <i>Journal on Multimodal User Interfaces</i> , 2019, 13, 31-40.	2.8	13

#	ARTICLE	IF	CITATIONS
253	Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules. <i>Cancer Cytopathology</i> , 2019, 127, 146-160.	2.6	39
254	Unraveling the effect of silent, intronic and missense mutations on <i>VWF</i> splicing: contribution of next generation sequencing in the study of mRNA. <i>Haematologica</i> , 2019, 104, 587-598.	3.5	14
255	CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 749-755.	3.5	53
256	Reassessing the electrophysiological evidence for categorical perception of Mandarin lexical tone: ERP evidence from native and non-native Mandarin listeners. <i>Attention, Perception, and Psychophysics</i> , 2019, 81, 543-557.	1.5	3
257	Focal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation. <i>Modern Pathology</i> , 2019, 32, 16-26.	5.8	35
258	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. <i>Cancer</i> , 2019, 125, 559-574.	4.1	75
259	Levels of CD8+ tumor infiltrating lymphocytes correlate with disease burden in bone marrow of therapy Naïve multiple myeloma patients. <i>Annals of Diagnostic Pathology</i> , 2019, 40, 174-175.	1.4	0
260	Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome. <i>Blood</i> , 2019, 134, 3016-3016.	1.4	5
261	Features of an Unusual AML with t(4;12)/Pdgra-ETV6 As the Sole Cytogenetic Abnormality Associated with Myelodysplastic Changes: A Case Report and Literature Review. <i>Blood</i> , 2019, 134, 5162-5162.	1.4	0
262	High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 5438-5438.	1.4	0
263	Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1719-1719.	1.4	1
264	NPM-ALK Upregulates Jab1/Csn5 through STAT3 Activation in Anaplastic Large Cell Lymphoma: A Novel Function of NPM-ALK That Contributes to PD1/PD-L1 Immune Checkpoint Regulation. <i>Blood</i> , 2019, 134, 2796-2796.	1.4	0
265	Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL). <i>Blood</i> , 2019, 134, 322-322.	1.4	0
266	MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients. <i>Blood</i> , 2019, 134, 1560-1560.	1.4	1
267	Gene Expression Profiling Using Nanostring Reveals Differences According to Location, Histology and MIPi Score in Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 5218-5218.	1.4	0
268	Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling. <i>Modern Pathology</i> , 2018, 31, 1036-1045.	5.8	65
269	Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2018, 24, 2304-2311.	7.3	12
270	Indolent T-lymphoblastic proliferation associated with low grade follicular dendritic cell sarcoma and Castleman disease. <i>Pathology</i> , 2018, 50, 351-352.	0.7	12

#	ARTICLE	IF	CITATIONS
271	Fifteen-Year Journey to High Reliability in Pathology and Laboratory Medicine. <i>American Journal of Medical Quality</i> , 2018, 33, 530-539.	0.6	2
272	Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. <i>Cancer</i> , 2018, 124, 2704-2713.	4.1	39
273	Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. <i>Clinical Cancer Research</i> , 2018, 24, 3967-3980.	7.3	74
274	Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. <i>American Journal of Surgical Pathology</i> , 2018, 42, 799-806.	4.0	31
275	Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement. <i>Aesthetic Surgery Journal</i> , 2018, 38, .	2.4	6
276	8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. <i>Leukemia Research</i> , 2018, 66, 73-78.	1.1	29
277	A Three-State System Based on Branched DNA Hybrids. <i>Chemistry - A European Journal</i> , 2018, 24, 4562-4572.	3.9	2
278	Chronic lymphoproliferative disorder of NK cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. <i>European Journal of Haematology</i> , 2018, 100, 444-454.	2.3	18
279	International Mobility of Academics: Brain Drain and Brain Gain. <i>European Management Review</i> , 2018, 15, 329-339.	3.8	28
280	Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations. <i>British Journal of Haematology</i> , 2018, 181, 305-305.	2.8	10
281	Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. <i>Human Pathology</i> , 2018, 74, 5-16.	2.4	82
282	3q26/ EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. <i>Leukemia Research</i> , 2018, 65, 25-28.	1.1	7
283	Delta-like homolog1/GATA binding protein 2 axis mediates leptin inhibition of PPAR β expression in hepatic stellate cells in vitro. <i>Life Sciences</i> , 2018, 192, 183-189.	4.4	4
284	Zircon (Hf, O isotopes) as melt indicator: Melt infiltration and abundant new zircon growth within melt rich layers of granulite-facies lenses versus solid-state recrystallization in hosting amphibolite-facies gneisses (central Erzgebirge, Bohemian Massif). <i>Lithos</i> , 2018, 302-303, 65-85.	1.6	14
285	A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2018, 54, 61-66.	2.0	56
286	Bone marrow findings in blast phase of polycythemia vera. <i>Annals of Hematology</i> , 2018, 97, 425-434.	1.9	14
287	Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 492-499.	4.0	14
288	MDM2 Amplification in Intrahepatic Cholangiocarcinomas. <i>American Journal of Surgical Pathology</i> , 2018, 42, 512-521.	4.0	26

#	ARTICLE	IF	CITATIONS
289	Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. <i>Cancer</i> , 2018, 124, 2561-2569.	4.1	14
290	Reply to Lambros et al. <i>Modern Pathology</i> , 2018, 31, 541-542.	5.8	0
291	Molecular insights into <i>Cassava brown streak virus</i> susceptibility and resistance by profiling of the early host response. <i>Molecular Plant Pathology</i> , 2018, 19, 476-489.	4.3	41
292	CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. <i>Modern Pathology</i> , 2018, 31, 327-336.	5.8	48
293	Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. <i>Clinical Cancer Research</i> , 2018, 24, 521-531.	7.3	66
294	Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. <i>Modern Pathology</i> , 2018, 31, 307-312.	5.8	25
295	DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1/2-CREB-Jmjd3 pathway. <i>Molecular Psychiatry</i> , 2018, 23, 1410-1420.	8.2	69
296	Comprehensive use of extended exome analysis improves diagnostic yield in rare disease: a retrospective survey in 1,059 cases. <i>Genetics in Medicine</i> , 2018, 20, 303-312.	2.5	63
297	Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 293-305.	4.0	83
298	Lymphoproliferative disorders with concurrent <i>HHV8</i> and <i>EBV</i> infection: beyond primary effusion lymphoma and germinotropic lymphoproliferative disorder. <i>Histopathology</i> , 2018, 72, 855-861.	3.1	20
299	Psychometric testing of the Family Carer Diabetes Management Self-Efficacy Scale. <i>Health and Social Care in the Community</i> , 2018, 26, 214-223.	1.7	8
300	Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. <i>American Journal of Surgical Pathology</i> , 2018, 42, 569-577.	4.0	10
301	Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. <i>Blood Reviews</i> , 2018, 32, 8-28.	6.3	71
302	Within-day variability in microbial concentrations at a UK designated bathing water: Implications for regulatory monitoring and the application of predictive modelling based on historical compliance data. <i>Water Research X</i> , 2018, 1, 100006.	6.2	19
303	Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8937-8942.	2.1	2
304	Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. <i>Blood Advances</i> , 2018, 2, 1334-1343.	5.5	24
305	Cancer Therapy-associated Lymphoproliferative Disorders. <i>American Journal of Surgical Pathology</i> , 2018, 42, 116-129.	4.0	29
306	Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2018, 8, 351.	3.0	76

#	ARTICLE	IF	CITATIONS
307	First Reported Case of Composite Breast Implant-associated Anaplastic Large Cell Lymphoma and Marginal Zone Lymphoma. <i>American Journal of Clinical Pathology</i> , 2018, 150, S100-S101.	0.8	0
308	Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. <i>Leukemia Research</i> , 2018, 73, 86-94.	1.1	30
309	Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. <i>Cancer</i> , 2018, 124, 3849-3855.	4.1	19
310	Chronic Myeloid Leukemia: Beyond BCR-ABL1. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 435-445.	2.4	42
311	Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 639-646.	1.3	9
312	Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. <i>PLoS ONE</i> , 2018, 13, e0204218.	2.4	25
313	Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6. <i>Oncotarget</i> , 2018, 9, 10987-10994.	1.8	7
314	Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. <i>Oncotarget</i> , 2018, 9, 10259-10271.	1.8	29
315	Granular B-acute lymphoblastic leukemia: Ultrastructural characterization of cytoplasmic granules. <i>Leukemia Research</i> , 2018, 73, 105-107.	1.1	0
316	Oral iron as treatment for iron deficiency: Should it always be the first choice?. <i>Medicina Clínica (English Edition)</i> , 2018, 151, e27-e28.	0.2	0
317	Myelodysplastic Syndromes with EZH2 Mutations Frequently Show Multilineage Dysplasia, Chromosome 7 Alterations and Concomitant Mutations in ASXL1, RUNX1 and TET2. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S260.	0.4	0
318	Kikuchi disease: an unusual case with features suggesting an infectious aetiology. <i>Pathology</i> , 2018, 50, 694-697.	0.7	2
319	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. <i>Blood Advances</i> , 2018, 2, 1807-1816.	5.5	39
320	Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID). <i>Blood Advances</i> , 2018, 2, 1386-1392.	5.5	24
321	Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. <i>Blood Advances</i> , 2018, 2, 1818-1827.	5.5	11
322	MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. <i>Modern Pathology</i> , 2018, 31, 1470-1478.	5.8	51
323	Characterization of chronic myelomonocytic leukemia with TP53 mutations. <i>Leukemia Research</i> , 2018, 70, 97-99.	1.1	8
324	Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. <i>Modern Pathology</i> , 2018, 31, 1717-1732.	5.8	36

#	ARTICLE	IF	CITATIONS
325	Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. <i>Human Pathology</i> , 2018, 82, 215-231.	2.4	11
326	Advances in pathological understanding of high-grade B cell lymphomas. <i>Expert Review of Hematology</i> , 2018, 11, 637-648.	2.2	20
327	Higher body mass index is associated with better survival in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2018, 71, 63-66.	1.1	5
328	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , 2018, 20, 574-593.	5.4	67
329	A Newly Recognized Histologic Pattern of IgG4-related Lymphadenopathy. <i>American Journal of Surgical Pathology</i> , 2018, 42, 977-982.	4.0	15
330	High molecular weight hyaluronan protects cartilage from degradation by inhibiting aggrecanase expression. <i>Journal of Orthopaedic Research</i> , 2018, 36, 3247-3255.	2.4	13
331	A multimodality workup of patients with Hypereosinophilia. <i>American Journal of Hematology</i> , 2018, 93, 1337-1346.	4.3	14
332	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with <i>FLT3</i> internal tandem duplication and worse relapse-free survival. <i>American Journal of Hematology</i> , 2018, 93, 1376-1383.	4.3	17
333	Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and <i>ALL</i> like mutations. <i>American Journal of Hematology</i> , 2018, 93, 1358-1367.	4.3	40
334	Myeloid neoplasms with t(16;21)(q24;q22)/ <i>RUNX1-RUNX1T3</i> mimics acute myeloid leukemia with <i>RUNX1-RUNX1T1</i> . <i>Annals of Hematology</i> , 2018, 97, 1775-1783.	1.9	12
335	Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. <i>Blood</i> , 2018, 132, 544-547.	1.4	106
336	Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with <i>MYC</i> Rearrangement with and without <i>BCL2</i> and/or <i>BCL6</i> Rearrangements: A Retrospective Analysis from 15 US Academic Centers. <i>Blood</i> , 2018, 132, 451-451.	1.4	3
337	Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. <i>Blood</i> , 2018, 132, 4151-4151.	1.4	5
338	Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients. <i>Blood</i> , 2018, 132, 1599-1599.	1.4	2
339	The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. <i>PLoS ONE</i> , 2018, 13, e0191461.	2.4	26
340	CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases. <i>Oncotarget</i> , 2018, 9, 11441-11450.	1.8	29
341	Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. <i>Oncotarget</i> , 2018, 9, 8441-8449.	1.8	27
342	<i>MET</i> amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 12959-12970.	1.8	13

#	ARTICLE	IF	CITATIONS
343	Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of 172 Patients. <i>Blood</i> , 2018, 132, 1600-1600.	1.4	0
344	Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience. <i>Blood</i> , 2018, 132, 4651-4651.	1.4	0
345	RAS and TP53, Not NOTCH1, Can Predict Survival in Adults with Acute T-Cell Lymphoblastic Leukemia Treated with Hypercvad. <i>Blood</i> , 2018, 132, 4085-4085.	1.4	0
346	Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. <i>Modern Pathology</i> , 2017, 30, 499-508.	5.8	120
347	Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. <i>Modern Pathology</i> , 2017, 30, 734-744.	5.8	28
348	Additional "structural" chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. <i>Modern Pathology</i> , 2017, 30, 843-853.	5.8	8
349	NF- κ B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. <i>Modern Pathology</i> , 2017, 30, 854-876.	5.8	16
350	mRNA profilin identifies low levels of phosphatases dual-specific phosphatase-7 (DUSP7) and cell division cycle-25B (CDC25B) in patients with early arthritis. <i>Clinical and Experimental Immunology</i> , 2017, 189, 113-119.	2.7	9
351	Clinical and pathological characteristics of HIV- and HHV-8 "negative Castleman disease. <i>Blood</i> , 2017, 129, 1658-1668.	1.4	131
352	Myeloid neoplasms with concurrent <i>BCR-ABL1</i> and <i>CBFB</i> rearrangements: A series of 10 cases of a clinically aggressive neoplasm. <i>American Journal of Hematology</i> , 2017, 92, 520-528.	4.3	24
353	Two cases of Legg-Perthes and intellectual disability in Tricho-Rhino-Phalangeal syndrome type 1 associated with novel <i>TRPS1</i> mutations. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1663-1667.	1.5	4
354	Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 441-447.	4.3	28
355	Immunophenotypic Shifts in Primary Cutaneous $\gamma\delta$ T-Cell Lymphoma Suggest Antigenic Modulation. <i>American Journal of Surgical Pathology</i> , 2017, 41, 431-445.	4.0	13
356	U.S. Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Plastic and Reconstructive Surgery</i> , 2017, 139, 1042-1050.	1.6	281
357	Characterization of <i>TP53</i> mutations in clonal cytopenia of undetermined significance. <i>American Journal of Hematology</i> , 2017, 92, E175-E177.	4.3	4
358	Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. <i>Haematologica</i> , 2017, 102, 1511-1518.	3.5	38
359	Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2017, 92, E168-E171.	4.3	5
360	Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature. <i>Histopathology</i> , 2017, 70, 821-831.	3.1	13

#	ARTICLE	IF	CITATIONS
361	Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. <i>Annals of Hematology</i> , 2017, 96, 501-504.	1.9	6
362	Mantle Cell Lymphoma With MYC Rearrangement. <i>American Journal of Surgical Pathology</i> , 2017, 41, 216-224.	4.0	51
363	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2017, 187, 1700-1716.	4.2	40
364	Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 514-524.	3.0	22
365	Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 472-477.	1.4	68
366	Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta ($\gamma\delta$) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous $\gamma\delta$ T-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2017, 41, 204-215.	4.0	62
367	PD-L1 and Notch1 expression in KSHV/HHV-8 and EBV associated germinotropic lymphoproliferative disorder: case report and review of the literature. <i>Pathology</i> , 2017, 49, 430-435.	0.7	12
368	Morphologic and Molecular Characteristics of De Novo AML With <i>JAK2</i> V617F Mutation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 790-796.	5.4	12
369	3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Modern Pathology</i> , 2017, 30, 940-951.	5.8	5
370	Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. <i>British Journal of Haematology</i> , 2017, 178, 403-412.	2.8	60
371	Global Adverse Event Reports of Breast Implant-Associated ALCL: An International Review of 40 Government Authority Databases. <i>Plastic and Reconstructive Surgery</i> , 2017, 139, 1029-1039.	1.6	114
372	Dermal myeloid sarcoma as an initial presentation of acute myeloid leukemia. <i>Blood</i> , 2017, 129, 1056-1056.	1.4	4
373	Clinical significance of isolated del(7p) in myeloid neoplasms. <i>Leukemia Research</i> , 2017, 55, 18-22.	1.1	6
374	Pure erythroid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 292-296.	4.3	51
375	Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. <i>American Journal of Hematology</i> , 2017, 92, 232-237.	4.3	10
376	Paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenia in a patient with Merkel cell carcinoma and voltage-gated calcium channel antibodies. <i>Muscle and Nerve</i> , 2017, 56, 998-1000.	2.3	11
377	Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor- α inhibitor therapy and literature review. <i>Annals of Diagnostic Pathology</i> , 2017, 26, 16-22.	1.4	35
378	A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 255-264.	3.0	78

#	ARTICLE	IF	CITATIONS
379	Tetraploidy/near-tetraploidy acute myeloid leukemia. <i>Leukemia Research</i> , 2017, 53, 20-27.	1.1	13
380	Prognostic impact of <sc>CD</sc>5 expression in diffuse large Bâ€cell lymphoma in patients treated with rituximabâ€sc>EPOCH</sc>. <i>European Journal of Haematology</i> , 2017, 98, 415-421.	2.3	41
381	The survival outcome of patients with relapsed/refractory peripheral Tâ€cell lymphomaâ€not otherwise specified and angioimmunoblastic Tâ€cell lymphoma. <i>British Journal of Haematology</i> , 2017, 176, 750-758.	2.8	83
382	Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. <i>British Journal of Cancer</i> , 2017, 117, 1685-1688.	6.6	13
383	Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1075-1079.	1.5	28
384	Characterization of <i><sc>TP</sc>53</i> mutations in lowâ€grade myelodysplastic syndromes and myelodysplastic syndromes with a nonâ€complex karyotype. <i>European Journal of Haematology</i> , 2017, 99, 536-543.	2.3	20
385	Follicular lymphoma with hyaline-vascular Castleman-like features: analysis of 6 cases and review of the literature. <i>Human Pathology</i> , 2017, 68, 136-146.	2.4	18
386	Distinguishing Between Hepatosplenic T-cell Lymphoma and Tâ€cell Large Granular Lymphocytic Leukemia. <i>American Journal of Surgical Pathology</i> , 2017, 41, 82-93.	4.0	47
387	Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1309-1321.	4.0	33
388	Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2017, 30, 1688-1697.	5.8	49
389	Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells. <i>Pathology</i> , 2017, 49, 544-547.	0.7	6
390	Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. <i>Haematologica</i> , 2017, 102, 1661-1670.	3.5	68
391	Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosaiâ€Dorfman disease. <i>Modern Pathology</i> , 2017, 30, 1367-1377.	5.8	202
392	Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. <i>Modern Pathology</i> , 2017, 30, 1338-1366.	5.8	40
393	Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. <i>Modern Pathology</i> , 2017, 30, 1378-1386.	5.8	7
394	P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2017, 30, 194-203.	5.8	72
395	Synchronous presentation of intraâ€nodal follicular dendritic cell sarcoma and Castleman disease. <i>American Journal of Hematology</i> , 2017, 92, 478-479.	4.3	8
396	Dose adjustedâ€sc>EPOCH</sc>â€R and mediastinal disease may improve outcomes for patients with grayâ€zone lymphoma. <i>British Journal of Haematology</i> , 2017, 179, 503-506.	2.8	10

#	ARTICLE	IF	CITATIONS
397	<sc>PET</sc>â€”positive lymphadenopathy in <sc>CLL</sc>â€”Not always <sc>R</sc>ichter transformation. American Journal of Hematology, 2017, 92, 405-406.	4.3	8
398	Refractory hairy cell leukemiaâ€”variant. American Journal of Hematology, 2017, 92, 1398-1399.	4.3	4
399	Epsteinâ€”Barr virus latent membrane proteinâ€”1 upâ€”regulates cytokines and correlates with older age and poorer prognosis in Hodgkin lymphoma. Histopathology, 2017, 70, 442-455.	3.1	17
400	Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Advances, 2017, 1, 2541-2552.	5.5	37
401	Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. Journal of Clinical Oncology, 2017, 35, 2260-2267.	5.3	137
402	Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. PLoS ONE, 2017, 12, e0181968.	2.4	24
403	Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget, 2017, 8, 10845-10857.	1.8	16
404	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. Oncotarget, 2016, 7, 2401-2416.	1.8	97
405	Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. Journal of Medical Case Reports, 2016, 10, 209.	0.9	2
406	Commentary: Comparison of historical medical spending patterns among the BRICS and G7. Frontiers in Pharmacology, 2016, 7, 213.	3.7	2
407	High-grade Transformation of Low-grade B-cell Lymphoma. American Journal of Surgical Pathology, 2016, 40, e1-e16.	4.0	20
408	<i>MYC</i>/<i>BCL6</i> doubleâ€”hit lymphoma (<sc>DHL</sc>): a tumour associated with an aggressive clinical course and poor prognosis. Histopathology, 2016, 68, 1090-1098.	3.1	85
409	Prognostic Factors of Hepatosplenic T-cell Lymphoma. American Journal of Surgical Pathology, 2016, 40, 676-688.	4.0	68
410	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Archives of Pathology and Laboratory Medicine, 2016, 140, 1225-1227.	2.6	6
411	Impact of oncogene rearrangement patterns on outcomes in patients with doubleâ€”hit nonâ€”Hodgkin lymphoma. Cancer, 2016, 122, 559-564.	4.1	69
412	Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Modern Pathology, 2016, 29, 1118-1142.	5.8	41
413	Chunking as the result of an efficiency computation trade-off. Nature Communications, 2016, 7, 12176.	13.2	90
414	A rare histologic variant of a common lymphoma. Blood, 2016, 128, 3012-3012.	1.4	0

#	ARTICLE	IF	CITATIONS
415	<i>CCND1-IGH</i> Fusion-Amplification and <i>MYC</i> Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2016, 146, 747-752.	0.8	10
416	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 3083-3100.	1.4	66
417	Starry Sky Pattern in Hematopoietic Neoplasms: A Review of Pathophysiology and Differential Diagnosis. <i>Advances in Anatomic Pathology</i> , 2016, 23, 343-355.	4.4	6
418	Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. <i>Cancer Genetics</i> , 2016, 209, 205-214.	0.4	8
419	Clinical and Biologic Significance of <i>MYC</i> Genetic Mutations in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 3593-3605.	7.3	51
420	Preleukemic phase of chronic myelogenous leukemia: morphologic and immunohistochemical characterization of 7 cases. <i>Annals of Diagnostic Pathology</i> , 2016, 21, 53-58.	1.4	13
421	Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms. <i>Modern Pathology</i> , 2016, 29, 727-734.	5.8	8
422	Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy. <i>American Journal of Clinical Pathology</i> , 2016, 145, 271-276.	0.8	11
423	Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. <i>Modern Pathology</i> , 2016, 29, 753-763.	5.8	249
424	Advances in B-lymphoblastic leukemia: cytogenetic and genomic lesions. <i>Annals of Diagnostic Pathology</i> , 2016, 23, 43-50.	1.4	11
425	Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. <i>Blood</i> , 2016, 127, 2742-2750.	1.4	155
426	Implementation of Genotyping Cell Free Nucleic Acid in Plasma Using Next Generation Sequencing Platforms in a Clinical Laboratory. <i>Cancer Genetics</i> , 2016, 209, 291-292.	0.4	0
427	Validation of a Multiplex Capillary Electrophoresis-Based Assay for Simultaneous Detection of the Common and Uncommon BCR-ABL1 Transcripts. <i>Cancer Genetics</i> , 2016, 209, 289-290.	0.4	0
428	TG2 and NF- κ B Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy. <i>Cancer Research</i> , 2016, 76, 6410-6423.	0.9	53
429	Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, E478-E479.	4.3	25
430	Sole rearrangement but not amplification of <i><sc>MYC</sc></i> is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. <i>British Journal of Haematology</i> , 2016, 175, 631-640.	2.8	56
431	Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature. <i>Human Pathology</i> , 2016, 58, 72-77.	2.4	34
432	Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 676-687.	3.0	16

#	ARTICLE	IF	CITATIONS
433	Hydroa vacciniforme and hydroa vacciniforme-like T-cell lymphoma: an uncommon event for transformation. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1102-1111.	1.5	19
434	On the significance of negative-pressure wound therapy with instillation in dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 786-795.	0.7	5
435	Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: a diagnostic dilemma for clinical cytogeneticists. <i>Molecular Cytogenetics</i> , 2016, 9, 62.	1.0	9
436	Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1036-1043.	4.3	43
437	Polyclonality in Sclerosing Angiomatoid Nodular Transformation of the Spleen. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1343-1351.	4.0	30
438	Donor-Derived T-Cell Large Granular Lymphocytic Leukemia in a Patient With Peripheral T-Cell Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 939-944.	5.4	9
439	High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis. <i>American Journal of Surgical Pathology</i> , 2016, 40, 253-261.	4.0	52
440	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1228-1230.	2.6	3
441	Crystal-storing histiocytosis: a clinicopathological study of 13 cases. <i>Histopathology</i> , 2016, 68, 482-491.	3.1	63
442	Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma in a patient treated with azathioprine for ulcerative colitis. <i>Pathology</i> , 2016, 48, 513-515.	0.7	6
443	Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2016, 145, 769-777.	0.8	40
444	Implementation of next generation sequencing in clinical molecular diagnostic laboratories: advantages, challenges and potential. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 109-120.	0.6	26
445	Isolated Sex Chromosome Loss after Allogeneic Stem Cell Transplant in Patients With Hematological Malignancies. <i>Cancer Genetics</i> , 2016, 209, 241.	0.4	0
446	Clinical significance of acquired loss of the X chromosome in bone marrow. <i>Leukemia Research</i> , 2016, 47, 109-113.	1.1	9
447	Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 461-472.	3.4	34
448	Constitutional pericentric inversion of chromosome 9 has no impact on survival in chronic myelogenous leukemia. <i>Annals of Hematology</i> , 2016, 95, 657-659.	1.9	2
449	Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors. <i>American Journal of Clinical Pathology</i> , 2016, 145, 222-237.	0.8	95
450	The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia. <i>Modern Pathology</i> , 2016, 29, 444-451.	5.8	19

#	ARTICLE	IF	CITATIONS
451	Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. <i>American Journal of Clinical Pathology</i> , 2016, 145, 418-427.	0.8	6
452	Immune checkpoint blockade: Releasing the brake towards hematological malignancies. <i>Blood Reviews</i> , 2016, 30, 189-200.	6.3	34
453	Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 48-56.	10.2	194
454	Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-associated Anaplastic Large-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 160-168.	5.3	359
455	Chronic myelomonocytic leukemia with nucleophosmin (<i>NPM1</i>) mutation. <i>European Journal of Haematology</i> , 2016, 96, 65-71.	2.3	46
456	Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 445-447.	1.4	5
457	MYC Copy Number Aberrancies Predict a Worse Prognosis in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 154-154.	1.4	1
458	Routine Clinical Testing for Actionable Mutations in CLL Using Endcll Assay V1: The Initial MD Anderson Experience. <i>Blood</i> , 2016, 128, 3196-3196.	1.4	1
459	Benefit of Consolidative Autologous Stem Cell Transplantation in First Complete Remission for Patients with Double Hit Lymphoma Appears Dependent on Induction Regimen Intensity. <i>Blood</i> , 2016, 128, 3455-3455.	1.4	2
460	The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4153-4153.	1.4	2
461	Cytogenetic Abnormalities May Predict Transformation to Acute Myeloid Leukemia in Polycythemia Vera Patients. <i>Blood</i> , 2016, 128, 4258-4258.	1.4	1
462	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. <i>Aging</i> , 2016, 8, 345-365.	3.0	19
463	RelA NF- κ B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , 2016, 8, 3321-3340.	3.0	30
464	Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 80599-80611.	1.8	26
465	Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in <i>SETBP1</i> , <i>SRSF2</i> , <i>ASXL1</i> and <i>NRAS</i> . <i>Oncotarget</i> , 2016, 7, 14251-14258.	1.8	44
466	Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with <i>MYC/BCL2</i> double hit lymphoma. <i>Oncotarget</i> , 2016, 7, 38122-38132.	1.8	30
467	Validation of the 2016 Revision to the World Health Organization (WHO) Classification of Myelodysplastic Syndromes with Diploid Karyotype. <i>Blood</i> , 2016, 128, 4319-4319.	1.4	0
468	CD5 Negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Cases. <i>Blood</i> , 2016, 128, 2964-2964.	1.4	0

#	ARTICLE	IF	CITATIONS
469	Clinical Implementation of a Testing Algorithm for the Diagnosis of Ph-like B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 2915-2915.	1.4	0
470	Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S228.	0.4	0
471	Myeloproliferative Neoplasms with Calreticulin Mutations Exhibit Distinctive Morphologic Features. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S57.	0.4	0
472	MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S223.	0.4	0
473	Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. <i>Blood</i> , 2015, 125, 3360-3363.	1.4	23
474	Identification of a Novel Fusion Gene, <i>IRF2BP2-RARA</i> , in Acute Promyelocytic Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 19-22.	5.4	47
475	MYC Cytogenetic Status Correlates With Expression and Has Prognostic Significance in Patients With MYC/BCL2 Protein Double-positive Diffuse Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1250-1258.	4.0	51
476	Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1132-1139.	4.0	68
477	Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 882-887.	4.3	14
478	Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 509-516.	2.8	15
479	Factors affecting the success of next-generation sequencing in cytology specimens. <i>Cancer Cytopathology</i> , 2015, 123, 659-668.	2.6	132
480	Characteristics and Treatment of Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma Presenting with Aggressive Features. <i>Plastic and Reconstructive Surgery</i> , 2015, 136, 119-120.	1.6	31
481	Malignant Effusions Correlate With Poorer Prognosis in Patients With Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2015, 143, 707-715.	0.8	29
482	Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells. <i>Modern Pathology</i> , 2015, 28, 1130-1137.	5.8	7
483	The Utility of BRAF V600E Mutation-Specific Antibody VE1 for the Diagnosis of Hairy Cell Leukemia. <i>American Journal of Clinical Pathology</i> , 2015, 143, 120-125.	0.8	24
484	Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: Kinetics of its appearance and potential predictive role in infectious complications. <i>Leukemia Research</i> , 2015, 39, 88-91.	1.1	20
485	Flow cytometry immunophenotypic analysis of philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features. <i>Cytometry Part B - Clinical Cytometry</i> , 2015, 88, 236-243.	1.7	4
486	Isolated +15 in bone marrow: Disease-associated or a benign finding?. <i>Leukemia Research</i> , 2015, 39, 72-76.	1.1	12

#	ARTICLE	IF	CITATIONS
487	Modelling rates of gasification of a char particle in chemical looping combustion. Proceedings of the Combustion Institute, 2015, 35, 2785-2792.	4.5	13
488	Survival Predictors in Acute Respiratory Distress Syndrome With Extracorporeal Membrane Oxygenation. Annals of Thoracic Surgery, 2015, 99, 243-250.	1.4	42
489	Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leukemia Research, 2015, 39, 348-354.	1.1	117
490	Epstein-Barr virus-positive plasmacytoma in immunocompetent patients. Histopathology, 2015, 67, 225-234.	3.1	33
491	B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas. Modern Pathology, 2015, 28, 208-217.	5.8	77
492	Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 855-859.	2.1	36
493	Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. Clinical Cancer Research, 2015, 21, 2644-2651.	7.3	72
494	CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Modern Pathology, 2015, 28, 787-798.	5.8	27
495	Isolated del(5q) in Patients Following Therapies for Various Malignancies May Not All Be Clinically Significant. American Journal of Clinical Pathology, 2015, 144, 78-86.	0.8	13
496	B-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 2015, 144, 333-340.	0.8	16
497	Extramedullary Manifestations of Myeloid Neoplasms. American Journal of Clinical Pathology, 2015, 144, 219-239.	0.8	98
498	Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Modern Pathology, 2015, 28, 1225-1235.	5.8	24
499	Introduction to the 2013 Workshop of the Society for Hematopathology/European Association for Haematopathology. American Journal of Clinical Pathology, 2015, 144, 4-5.	0.8	0
500	Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2015, 21, 1948-1954.	2.1	66
501	Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry. American Journal of Surgical Pathology, 2015, 39, 454-461.	4.0	25
502	Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart. Histopathology, 2015, 67, 625-635.	3.1	26
503	Similarity computation using semantic networks created from web-harvested data. Natural Language Engineering, 2015, 21, 49-79.	2.5	21
504	The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. American Journal of Hematology, 2015, 90, 504-510.	4.3	33

#	ARTICLE	IF	CITATIONS
505	Clinical Validation of a Multipurpose Assay for Detection and Genotyping of <i>CALR</i> Mutations in Myeloproliferative Neoplasms. <i>American Journal of Clinical Pathology</i> , 2015, 144, 746-755.	0.8	8
506	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015, 28, 1555-1573.	5.8	49
507	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , 2015, 28, 1297-1314.	5.8	22
508	$\text{TP}53$ overexpression is an independent adverse prognostic factor in <i>de novo</i> myelodysplastic syndromes with fibrosis. <i>British Journal of Haematology</i> , 2015, 171, 91-99.	2.8	45
509	Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. <i>Modern Pathology</i> , 2015, 28, 1014-1022.	5.8	20
510	Evaluation of NF- κ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , 2015, 28, 1202-1213.	5.8	18
511	T-Lymphoblastic Leukemia/Lymphoma. <i>American Journal of Clinical Pathology</i> , 2015, 144, 411-422.	0.8	108
512	Hematolymphoid Neoplasms Associated With Rearrangements of PDGFRA, PDGFRB, and FGFR1. <i>American Journal of Clinical Pathology</i> , 2015, 144, 377-392.	0.8	57
513	Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of $\hat{1}31$ T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With $\hat{1}31$ T-Cell Large Granular Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2015, 144, 607-619.	0.8	35
514	High Levels of Regulatory T Cells in Blood Are a Poor Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2015, 144, 935-944.	0.8	30
515	<i>De Novo MYC</i> and <i>BCL2</i> Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis. <i>Pediatric Hematology and Oncology</i> , 2015, 32, 535-547.	0.9	30
516	Acute Myeloid Leukemia with t(v;5q33-34) Does Not Always have Myelodysplastic Features but is Associated with Poor Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S187-S188.	0.4	0
517	Clinical and prognostic significance of 3q26 rearrangements and other chromosome 3 abnormalities in chronic myelogenous leukemia in era of tyrosine kinase inhibitors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S32-S33.	0.4	0
518	Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. <i>European Journal of Haematology</i> , 2015, 95, 168-176.	2.3	31
519	Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. <i>Modern Pathology</i> , 2015, 28, 373-382.	5.8	30
520	RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1730-1730.	1.4	3
521	In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. <i>Blood</i> , 2015, 126, 3192-3192.	1.4	3
522	Clinical and biological significance of <i>de novo</i> CD5+ diffuse large B-cell lymphoma in Western countries. <i>Oncotarget</i> , 2015, 6, 5615-5633.	1.8	75

#	ARTICLE	IF	CITATIONS
523	Prognostic impact of c-Rel nuclear expression and <i>REL</i> amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 23157-23180.	1.8	36
524	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. <i>Oncotarget</i> , 2015, 6, 13933-13945.	1.8	34
525	<i>MYC</i> -driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. <i>Oncotarget</i> , 2015, 6, 38591-38616.	1.8	47
526	Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2015, 126, 2011-2011.	1.4	1
527	<i>MYC/BCL2</i> Double Hit Lymphoma: What Really Matters. <i>Blood</i> , 2015, 126, 3909-3909.	1.4	0
528	B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease. <i>Modern Pathology</i> , 2014, 27, 382-389.	5.8	12
529	Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. <i>Journal of Hematology and Oncology</i> , 2014, 7, 74.	17.8	91
530	Knowledge of cervical cancer and attendance at cervical cancer screening: a survey of Black women in London. <i>BMC Public Health</i> , 2014, 14, 1096.	3.0	46
531	Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization. <i>Leukemia and Lymphoma</i> , 2014, 55, 2538-2548.	1.4	14
532	Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. <i>Modern Pathology</i> , 2014, 27, 681-689.	5.8	54
533	Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease. <i>Modern Pathology</i> , 2014, 27, 823-831.	5.8	84
534	Nonallele Specific Silencing of Ataxin-7 Improves Disease Phenotypes in a Mouse Model of SCA7. <i>Molecular Therapy</i> , 2014, 22, 1635-1642.	8.1	53
535	Bone marrow involvement by subcutaneous Panniculitis-like T-cell lymphoma: a report of three cases. <i>Modern Pathology</i> , 2014, 27, 800-807.	5.8	16
536	Utility of Quantitative Flow Cytometry Immunophenotypic Analysis of CD5 Expression in Small B-Cell Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 903-909.	2.6	13
537	Flow Cytometric Immunophenotypic Analysis of Systemic Mastocytosis Involving Bone Marrow. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1210-1214.	2.6	9
538	Quantitative Assessment of Mutant Allele Burden in Solid Tumors by Semiconductor-Based Next-Generation Sequencing. <i>American Journal of Clinical Pathology</i> , 2014, 141, 559-572.	0.8	20
539	Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. <i>Haematologica</i> , 2014, 99, 465-473.	3.5	167
540	Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. <i>American Journal of Hematology</i> , 2014, 89, 813-818.	4.3	70

#	ARTICLE	IF	CITATIONS
541	<i>BRAF</i> kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type <i>RAS</i> . <i>American Journal of Hematology</i> , 2014, 89, 499-504.	4.3	32
542	Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large B-cell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S146-S147.	0.4	0
543	TET2 Mutations, Myelodysplastic Features, and a Distinct Immunoprofile Characterize Blastic Plasmacytoid Dendritic Cell Neoplasm in the Bone Marrow. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S128.	0.4	0
544	CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. <i>Leukemia and Lymphoma</i> , 2014, 55, 624-627.	1.4	36
545	Indolent peripheral T-cell lymphoma involving the gastrointestinal tract. <i>Human Pathology</i> , 2014, 45, 421-426.	2.4	41
546	Differential Expression of CD200 in B-Cell Neoplasms by Flow Cytometry Can Assist in Diagnosis, Subclassification, and Bone Marrow Staging. <i>American Journal of Clinical Pathology</i> , 2014, 142, 837-844.	0.8	67
547	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in <i>De Novo</i> Diffuse Large B-Cell Lymphoma in Western Countries. <i>Clinical Cancer Research</i> , 2014, 20, 2338-2349.	7.3	119
548	Subtle bilirubin-induced neurodevelopmental dysfunction (BIND) in the term and late preterm infant: Does it exist?. <i>Seminars in Perinatology</i> , 2014, 38, 465-471.	2.6	15
549	Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 114-120.	5.3	341
550	Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm. <i>Modern Pathology</i> , 2014, 27, 1137-1143.	5.8	44
551	The oncogenic <i>JUNB</i> / <i>CD</i> 30 axis contributes to cell cycle deregulation in <i>ALK</i> + anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2014, 167, 514-523.	2.8	25
552	Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 1-14.	2.6	136
553	Acquired B cell immunophenotype of follicular dendritic cells in a B cell-depleted lymph node after treatment with rituximab. <i>Annals of Hematology</i> , 2014, 93, 1947-1948.	1.9	3
554	Rearrangements of <i>MYC</i> gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2014, 27, 958-971.	5.8	114
555	Clinical Implications of Phosphorylated STAT3 Expression in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 5113-5123.	7.3	61
556	Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Cancer</i> , 2014, 120, 1818-1829.	4.1	33
557	Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 203-209.	1.4	22
558	Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. <i>Leukemia Research</i> , 2014, 38, 896-900.	1.1	8

#	ARTICLE	IF	CITATIONS
559	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014, 124, 2354-2361.	1.4	396
560	A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. <i>Blood</i> , 2014, 124, 3768-3771.	1.4	91
561	Integrated Genome Sequencing Reveals Frequent Loss of Function Alterations of ARID1A and Other Epigenetic Modifiers in Sezary Syndrome. <i>Blood</i> , 2014, 124, 706-706.	1.4	2
562	NF- κ B Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2014, 124, 1620-1620.	1.4	0
563	Comparison of Risk Models for Patients with Lower Risk Myelodysplastic Syndromes. <i>Blood</i> , 2014, 124, 1919-1919.	1.4	0
564	Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes. <i>Blood</i> , 2014, 124, 4658-4658.	1.4	0
565	Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL). <i>Blood</i> , 2014, 124, 2563-2563.	1.4	1
566	Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2014, 124, 143-143.	1.4	1
567	Novel Gene Translocations Involving TYK2 in Cutaneous CD30-Positive Lymphoproliferative Disorders. <i>Blood</i> , 2014, 124, 3032-3032.	1.4	1
568	Clinical and Biological Features of Primary Testicular B-Cell Lymphoma - a Single-Institution Study of 89 Cases. <i>Blood</i> , 2014, 124, 3036-3036.	1.4	0
569	MYC Expression Is Prognostic in Therapy Related Acute Myeloid Leukemia (AML) and AML with Myelodysplastic Syndrome (MDS)-Related Changes. <i>Blood</i> , 2014, 124, 5334-5334.	1.4	0
570	Molecular characterization of <i>de novo</i> Philadelphia chromosome-positive acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 138-144.	1.4	110
571	Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 607-622.	3.0	317
572	The Impact of MYC Rearrangements and "Double Hit" Abnormalities in Diffuse Large B-Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 243-252.	2.4	30
573	Genomic Variation by Whole-Genome SNP Mapping Arrays Predicts Time-to-Event Outcome in Patients with Chronic Lymphocytic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 196-209.	3.0	24
574	t(15;17)(q24.1;q21.2)/PML-RARA in blast phase of chronic myelogenous leukemia: a rare form of clonal evolution. <i>Journal of Hematopathology</i> , 2013, 6, 187-193.	0.5	6
575	Donor-derived isolated del(20q) after hematopoietic stem cell transplantation: report of two cases and review of the literature. <i>Journal of Hematopathology</i> , 2013, 6, 25-32.	0.5	3
576	The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. <i>Annals of Hematology</i> , 2013, 92, 1335-1343.	1.9	22

#	ARTICLE	IF	CITATIONS
577	CXC Chemokine Receptor 4 Expression, CXC Chemokine Receptor 4 Activation, and Wild-Type Nucleophosmin Are Independently Associated With Unfavorable Prognosis in Patients With Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 686-692.	0.4	16
578	High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 991-994.	2.1	36
579	Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chromosomal abnormalities in <sc>SM</sc> and <sc>AHNMD</sc> components. <i>American Journal of Hematology</i> , 2013, 88, 219-224.	4.3	78
580	Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma. <i>Modern Pathology</i> , 2013, 26, 1338-1345.	5.8	38
581	Micro<sc>RNA</sc> signatures and treatment response in patients with advanced classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013, 162, 336-347.	2.8	39
582	<i>TP53</i> mutation is rare in primary myelofibrosis. <i>Leukemia and Lymphoma</i> , 2013, 54, 1552-1552.	1.4	5
583	Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 220-226.	3.0	202
584	Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-CHOP: A Report From an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, S382.	0.4	1
585	Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications. <i>Human Pathology</i> , 2013, 44, 2658-2667.	2.4	20
586	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	1.4	614
587	Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q). <i>Cancer Genetics</i> , 2013, 206, 42-46.	0.4	16
588	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	1.4	209
589	Potential therapeutic biomarkers in plasma cell myeloma: A flow cytometry study. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84B, 222-228.	1.7	23
590	Transcription and Translation are Primary Targets of Pim Kinase Inhibitor SGI-1776 in Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, S383.	0.4	0
591	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. <i>Haematologica</i> , 2013, 98, 255-263.	3.5	143
592	Differential expression of aurora-A kinase in T-cell lymphomas. <i>Modern Pathology</i> , 2013, 26, 640-647.	5.8	25
593	TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation. <i>Modern Pathology</i> , 2013, 26, 195-203.	5.8	19
594	Immunostaining for Rapid Diagnosis of Acute Promyelocytic Leukemia with the Tetramethylrhodamine-5-Isothiocyanate-“Conjugated Anti-“Promyelocytic Leukemia Monoclonal Antibody PG-M3. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1669-1673.	2.6	7

#	ARTICLE	IF	CITATIONS
595	Myeloid Sarcoma of the Head and Neck Region. Archives of Pathology and Laboratory Medicine, 2013, 137, 1560-1568.	2.6	41
596	Clinicopathologic Features of CD5-Positive Nodal Marginal Zone Lymphoma. American Journal of Clinical Pathology, 2013, 140, 693-700.	0.8	26
597	MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma. Advances in Anatomic Pathology, 2013, 20, 315-326.	4.4	72
598	Iatrogenic Immunodeficiency-associated Classical Hodgkin Lymphoma. American Journal of Surgical Pathology, 2013, 37, 1895-1897.	4.0	10
599	Phenotypic evolution in a case of peripheral T-cell lymphoma suggests the presence of tumor heterogeneity. Journal of Cutaneous Pathology, 2013, 40, 573-579.	1.5	6
600	The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms. Frontiers in Oncology, 2013, 3, 169.	3.0	44
601	TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. American Journal of Hematology, 2013, 88, 1055-1061.	4.3	125
602	Effects of High-Dose Radiotherapy on Implantable Cardioverter Defibrillators: An In Vivo Porcine Study. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 1558-1563.	1.2	16
603	Cytarabine, Ki67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Cancer, 2013, 119, 3318-3325.	4.1	5
604	CD105 (Endoglin) Is Highly Overexpressed in a Subset of Cases of Acute Myeloid Leukemias. American Journal of Clinical Pathology, 2013, 140, 370-378.	0.8	18
605	Landscape of DNA Virus Associations across Human Malignant Cancers: Analysis of 3,775 Cases Using RNA-Seq. Journal of Virology, 2013, 87, 8916-8926.	3.4	194
606	Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2013, 54, 2631-2638.	1.4	38
607	Plasma Cell Enrichment Enhances Detection of High-Risk Cytogenomic Abnormalities by Fluorescence In Situ Hybridization and Improves Risk Stratification of Patients With Plasma Cell Neoplasms. Archives of Pathology and Laboratory Medicine, 2013, 137, 625-631.	2.6	23
608	Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4529-4540.	1.4	43
609	Classical Hodgkin Lymphoma Arising in the Setting of Iatrogenic Immunodeficiency. American Journal of Surgical Pathology, 2013, 37, 1290-1297.	4.0	38
610	Extranodal NK/T-cell Lymphoma, Nasal Type. American Journal of Surgical Pathology, 2013, 37, 14-23.	4.0	179
611	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 641-641.	1.4	3
612	STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 365-365.	1.4	1

#	ARTICLE	IF	CITATIONS
613	Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT). <i>Blood</i> , 2013, 122, 3350-3350.	1.4	0
614	MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 363-363.	1.4	0
615	Rapid Detection and Quantitation of BRAF Mutations in Hairy Cell Leukemia Using a Sensitive Pyrosequencing Assay. <i>American Journal of Clinical Pathology</i> , 2012, 138, 153-156.	0.8	37
616	Myelodysplastic Syndrome/Acute Myeloid Leukemia With t(3;21)(q26.2;q22) Is Commonly a Therapy-Related Disease Associated With Poor Outcome. <i>American Journal of Clinical Pathology</i> , 2012, 138, 146-152.	0.8	21
617	Somatic Deletions of the PolyA Tract in the 3' Untranslated Region of Epidermal Growth Factor Receptor Are Common in Microsatellite Instability-High Endometrial and Colorectal Carcinomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 510-516.	2.6	11
618	Usefulness of Flow Cytometric Immunophenotyping for Bone Marrow Staging in Patients With Mantle Cell Lymphoma After Therapy. <i>American Journal of Clinical Pathology</i> , 2012, 137, 634-640.	0.8	6
619	CD117 Expression Is a Sensitive but Nonspecific Predictor of FLT3 Mutation in T Acute Lymphoblastic Leukemia and T/Myeloid Acute Leukemia. <i>American Journal of Clinical Pathology</i> , 2012, 137, 213-219.	0.8	51
620	Molecular and Clinicopathologic Characterization of AML With Isolated Trisomy 4. <i>American Journal of Clinical Pathology</i> , 2012, 137, 387-394.	0.8	16
621	Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 990-992.	1.4	17
622	B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. <i>Modern Pathology</i> , 2012, 25, 145-156.	5.8	225
623	Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Modern Pathology</i> , 2012, 25, 237-245.	5.8	67
624	Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. <i>Modern Pathology</i> , 2012, 25, 1405-1412.	5.8	50
625	Breast implant-associated anaplastic large cell lymphoma: a newly recognized entity that needs further refinement of its definition. <i>Leukemia and Lymphoma</i> , 2012, 53, 749-750.	1.4	28
626	Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. <i>Journal of Experimental Medicine</i> , 2012, 209, 1553-1565.	8.8	278
627	N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. <i>Modern Pathology</i> , 2012, 25, 231-236.	5.8	52
628	Microscopic Diffuse Large B-Cell Lymphoma (DLBCL) Occurring in Pseudocysts. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1074-1080.	4.0	54
629	Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. <i>Haematologica</i> , 2012, 97, 1080-1084.	3.5	61
630	Capsular Contracture and Axillary Lymphadenopathy in Breast Implant-associated ALK-negative Anaplastic Large Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1736-1738.	4.0	6

#	ARTICLE	IF	CITATIONS
631	Anaplastic Large Cell Lymphoma Associated With Breast Implants. American Journal of Surgical Pathology, 2012, 36, 1000-1008.	4.0	156
632	Extranodal NK/T-cell Lymphoma, Nasal Type, Arising in Association With Saline Breast Implant. American Journal of Surgical Pathology, 2012, 36, 1729-1734.	4.0	33
633	Nonmyeloablative allogeneic transplantation with or without 90Yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood, 2012, 119, 6373-6378.	1.4	97
634	Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?. Haematologica, 2012, 97, 919-925.	3.5	41
635	Usefulness of CD11a and CD18 in Flow Cytometric Immunophenotypic Analysis for Diagnosis of Acute Promyelocytic Leukemia. American Journal of Clinical Pathology, 2012, 138, 744-750.	0.8	22
636	Extracavitary/solid variant of primary effusion lymphoma. Annals of Diagnostic Pathology, 2012, 16, 441-446.	1.4	65
637	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2012, 120, 3986-3996.	1.4	313
638	Florid reactive lymphoid hyperplasia (lymphoma-like lesion) of the uterine cervix. Annals of Diagnostic Pathology, 2012, 16, 21-28.	1.4	20
639	Detection of High-Frequency and Novel DNMT3A Mutations in Acute Myeloid Leukemia by High-Resolution Melting Curve Analysis. Journal of Molecular Diagnostics, 2012, 14, 336-345.	3.0	25
640	Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML. PLoS ONE, 2012, 7, e41485.	2.4	24
641	The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood, 2012, 119, 4017-4025.	1.4	80
642	Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer, 2012, 118, 2879-2888.	4.1	68
643	High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. Histopathology, 2012, 61, 945-954.	3.1	46
644	Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia. Leukemia Research, 2012, 36, 974-981.	1.1	31
645	Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. Cancer, 2012, 118, 112-117.	4.1	65
646	Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer, 2012, 118, 1566-1573.	4.1	65
647	Early Mixed T-Lymphocyte and Myeloid Chimerism Is Predictive of Disease Recurrence Following Allogeneic Stem Cell Transplantation for AML/MDS. Blood, 2012, 120, 3075-3075.	1.4	1
648	Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2012, 120, 544-544.	1.4	1

#	ARTICLE	IF	CITATIONS
649	Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Blood</i> , 2012, 120, 3554-3554.	1.4	0
650	Dasatinib Therapy Affects Bone Homeostasis in Patients with Chronic Myelogenous Leukemia in Chronic Phase Independently of Molecular Response. <i>Blood</i> , 2012, 120, 1682-1682.	1.4	0
651	Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 678-686.	3.0	46
652	4.27 Genomic Variability Predicts Time-to-Treatment in Previously Untreated CLL Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S237-S238.	0.4	0
653	Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2011, 12, 1222-1228.	10.2	171
654	Plasmablastic lymphoma involving the penis: a previously unreported location of a case with aberrant CD3 expression. <i>Pathology</i> , 2011, 43, 54-57.	0.7	25
655	A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2011, 6, e28277.	2.4	20
656	Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor- κ B-inducing kinase while activating both canonical and alternative nuclear factor- κ B pathways. <i>Blood</i> , 2011, 117, 200-210.	1.4	65
657	LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. <i>Blood</i> , 2011, 117, 4076-4084.	1.4	30
658	Transient/reversible ring sideroblasts in bone marrow of patients post cytotoxic therapies for primary malignancies. <i>Leukemia Research</i> , 2011, 35, 1605-1610.	1.1	10
659	Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. <i>Cancer</i> , 2011, 117, 4009-4017.	4.1	40
660	Phosphorylated CXCR4 is associated with poor survival in adults with acute lymphoblastic leukemia. <i>Cancer</i> , 2011, 117, 4689-4695.	4.1	39
661	The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy. <i>International Journal of Cancer</i> , 2011, 128, 2759-2764.	5.4	17
662	Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. <i>Leukemia Research</i> , 2011, 35, 351-357.	1.1	15
663	De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification. <i>Modern Pathology</i> , 2011, 24, 384-389.	5.8	47
664	Detection of Nucleophosmin 1 Mutations by Quantitative Real-Time Polymerase Chain Reaction Versus Capillary Electrophoresis: A Comparative Study. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 994-1000.	2.6	14
665	Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification. <i>Modern Pathology</i> , 2011, 24, 375-383.	5.8	95
666	Chronic Lymphocytic Leukemia With t(14;19)(q32;q13) Is Characterized by Atypical Morphologic and Immunophenotypic Features and Distinctive Genetic Features. <i>American Journal of Clinical Pathology</i> , 2011, 135, 686-696.	0.8	37

#	ARTICLE	IF	CITATIONS
667	<i>FLT3</i> and <i>NPM1</i> Mutations in Myelodysplastic Syndromes. American Journal of Clinical Pathology, 2011, 135, 62-69.	0.8	91
668	Refractory Anemia With Ring Sideroblasts Associated With Marked Thrombocytosis. American Journal of Clinical Pathology, 2011, 135, 398-403.	0.8	17
669	Acute Myeloid Leukemia With <i>IDH1</i> or <i>IDH2</i> Mutation. American Journal of Clinical Pathology, 2011, 135, 35-45.	0.8	149
670	Residual Monotypic Plasma Cells in Patients With Waldenström Macroglobulinemia After Therapy. American Journal of Clinical Pathology, 2011, 135, 365-373.	0.8	46
671	Chromosome 20q Deletion. American Journal of Clinical Pathology, 2011, 135, 391-397.	0.8	17
672	Myelodysplastic Syndrome With inv(3)(q21q26.2) or t(3;3)(q21;q26.2) Has a High Risk for Progression to Acute Myeloid Leukemia. American Journal of Clinical Pathology, 2011, 136, 282-288.	0.8	43
673	Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation. Blood, 2011, 118, 3072-3072.	1.4	9
674	Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,. Blood, 2011, 118, 3718-3718.	1.4	5
675	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2011, 118, 949-949.	1.4	3
676	12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years,. Blood, 2011, 118, 4138-4138.	1.4	0
677	Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 2695-2695.	1.4	11
678	Aberrant Expression of Golgin-84 in Non-Hodgkin Lymphomas and Plasma Cell Myeloma. Blood, 2011, 118, 4633-4633.	1.4	0
679	Side population of a murine mantle cell lymphoma model contains tumour-initiating cells responsible for lymphoma maintenance and dissemination. Journal of Cellular and Molecular Medicine, 2010, 14, 1532-1545.	3.6	19
680	Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood, 2010, 115, 1985-1992.	1.4	100
681	V(D)J recombination and staggered DNA breaks: guilty again. Blood, 2010, 115, 2121-2122.	1.4	2
682	8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. Blood, 2010, 116, 5622-5630.	1.4	20
683	High Serum Thymidine Kinase 1 Level Predicts Poorer Survival in Patients With Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 2010, 134, 472-477.	0.8	33
684	Benefit of Consolidative Radiation Therapy in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Chemotherapy. Journal of Clinical Oncology, 2010, 28, 4170-4176.	5.3	225

#	ARTICLE	IF	CITATIONS
685	Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494. <i>Clinical Cancer Research</i> , 2010, 16, 2435-2442.	7.3	25
686	Clonal Relationship of Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue Involving Different Sites. <i>American Journal of Clinical Pathology</i> , 2010, 134, 112-118.	0.8	34
687	Acute Promyelocytic Leukemia at Time of Relapse Commonly Demonstrates Cytogenetic Evidence of Clonal Evolution and Variability in Blast Immunophenotypic Features. <i>American Journal of Clinical Pathology</i> , 2010, 133, 484-490.	0.8	18
688	Primary T-cell lymphoblastic lymphoma of the cavernous sinus. <i>Journal of Neurosurgery: Pediatrics</i> , 2010, 5, 94-97.	1.4	12
689	A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Modern Pathology</i> , 2010, 23, 1524-1534.	5.8	13
690	Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. <i>Modern Pathology</i> , 2010, 23, 1518-1523.	5.8	19
691	Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. <i>Modern Pathology</i> , 2010, 23, 1113-1126.	5.8	31
692	HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis. <i>Modern Pathology</i> , 2010, 23, 381-391.	5.8	23
693	Flow cytometric detection of peripheral blood involvement by mycosis fungoides and SÅ©zary syndrome using T-cell receptor VÎ² chain antibodies and its application in blood staging. <i>Modern Pathology</i> , 2010, 23, 284-295.	5.8	59
694	Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. <i>Leukemia and Lymphoma</i> , 2010, 51, 1217-1224.	1.4	65
695	The Pan-Deacetylase Inhibitor Panobinostat Downregulates HIF-1Î± and VEGF and, Synergizes with Everolimus In Hodgkin Lymphoma Cell Lines. <i>Blood</i> , 2010, 116, 2851-2851.	1.4	6
696	Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 3964-3964.	1.4	6
697	Immunohistochemical Profile and Fluorescence In Situ Hybridization Analysis of Diffuse Large B-Cell Lymphoma in Northern China. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 759-765.	2.6	8
698	Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, e40-e47.	2.6	11
699	Acute Erythroid Leukemia. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 1261-1270.	2.6	47
700	Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms of the Ocular Adnexa. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 336-340.	2.6	2
701	Clusterin Expression Correlates With Stage and Presence of Large Cells in Mycosis Fungoides. <i>American Journal of Clinical Pathology</i> , 2009, 131, 511-515.	0.8	10
702	Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 904-910.	5.3	207

#	ARTICLE	IF	CITATIONS
703	Chronic Lymphocytic Leukemia With t(2;14)(p16;q32) Involves the <i>BCL11A</i> and <i>IgH</i> Genes and Is Associated With Atypical Morphologic Features and Unmutated <i>IgVH</i> Genes. <i>American Journal of Clinical Pathology</i> , 2009, 131, 663-670.	0.8	36
704	Postchemotherapy Histiocyte-Rich Pseudotumor Involving the Spleen. <i>American Journal of Clinical Pathology</i> , 2009, 132, 342-348.	0.8	15
705	Therapy-Related Acute Myeloid Leukemia With t(8;21)(q22;q22) Shares Many Features With De Novo Acute Myeloid Leukemia With t(8;21)(q22;q22) but Does Not Have a Favorable Outcome. <i>American Journal of Clinical Pathology</i> , 2009, 131, 647-655.	0.8	71
706	T-Cell Large Granular Lymphocyte Leukemia Associated With Myelodysplastic Syndrome. <i>American Journal of Clinical Pathology</i> , 2009, 131, 347-356.	0.8	41
707	Anaplastic large cell lymphoma in leukemic phase: Extraordinarily high white blood cell count. <i>Pathology International</i> , 2009, 59, 345-353.	1.4	35
708	Deletion 15q as the sole abnormality in acute myeloid leukemia: report of three cases and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2009, 188, 118-123.	1.0	5
709	del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2009, 192, 18-23.	1.0	6
710	Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine. <i>Cancer</i> , 2009, 115, 4727-4736.	4.1	19
711	Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. <i>Cancer</i> , 2009, 115, 4737-4744.	4.1	45
712	Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with <i>FLT3</i> internal tandem duplication and <i>NPM1</i> mutation. <i>Cancer</i> , 2009, 115, 5481-5489.	4.1	65
713	The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009, 14, 336-347.	4.9	49
714	Analysis of Aurora kinase A expression in CD34+ blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. <i>Journal of Hematopathology</i> , 2009, 2, 2-8.	0.5	43
715	Utility of the World Health Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. <i>Modern Pathology</i> , 2009, 22, 50-57.	5.8	40
716	Immunomodulator agent-related lymphoproliferative disorders. <i>Modern Pathology</i> , 2009, 22, 1532-1540.	5.8	74
717	Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. <i>Modern Pathology</i> , 2009, 22, 1023-1031.	5.8	112
718	Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-Cell lymphoma. <i>Modern Pathology</i> , 2009, 22, 1312-1320.	5.8	89
719	Aberrant Underexpression of CD81 in Precursor B-Cell Acute Lymphoblastic Leukemia. <i>American Journal of Clinical Pathology</i> , 2009, 132, 692-698.	0.8	57
720	Anaplastic large cell lymphoma: another entity in the differential diagnosis of small round blue cell tumors. <i>Annals of Diagnostic Pathology</i> , 2009, 13, 413-427.	1.4	23

#	ARTICLE	IF	CITATIONS
721	Nodular Lymphocyte Predominant Hodgkin Lymphoma With Clusters of LP Cells, Acute Inflammation, and Fibrosis. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1725-1731.	4.0	10
722	Pediatric Therapy-related Myelodysplastic Syndrome/Acute Myeloid Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 803-811.	0.6	53
723	Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. <i>Haematologica</i> , 2009, 94, 29-37.	3.5	82
724	Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. <i>Blood</i> , 2009, 113, 4144-4152.	1.4	197
725	Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma.. <i>Blood</i> , 2009, 114, 3744-3744.	1.4	4
726	Flow Cytometric Immunophenotyping of Anaplastic Large Cell Lymphoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 49-56.	2.6	49
727	Anaplastic Large Cell Lymphoma Involving the Breast: A Clinicopathologic Study of 6 Cases and Review of the Literature. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 1383-1390.	2.6	91
728	Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).. <i>Blood</i> , 2009, 114, 2310-2310.	1.4	1
729	Simultaneous Targeting of SHH/ p53 Pathways in Large B Cell Lymphomas.. <i>Blood</i> , 2009, 114, 1730-1730.	1.4	0
730	Aurora-A kinase nuclear expression in chronic lymphocytic leukemia. <i>Modern Pathology</i> , 2008, 21, 1428-1435.	5.8	13
731	Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations. <i>Modern Pathology</i> , 2008, 21, 1029-1036.	5.8	31
732	<i>MYC</i> translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. <i>British Journal of Haematology</i> , 2008, 142, 36-44.	2.8	78
733	Splenic marginal zone lymphomas are characterized by loss of interstitial regions of chromosome 7q, 7q31.32 and 7q36.2 that include the protection of telomere 1 (<i>POT1</i>) and sonic hedgehog (<i>SHH</i>) genes. <i>British Journal of Haematology</i> , 2008, 142, 216-226.	2.8	38
734	Type B Core Binding Factor β 2/Smooth Muscle Myosin Heavy Chain Fusion Transcript in Myeloid Blast Phase of Chronic Myeloid Leukemia: Correlation with Nuclear and Cytoplasmic Localization of the Fusion Protein. <i>Clinical Leukemia</i> , 2008, 2, 257-260.	0.3	2
735	Bone Marrow Involvement by Marginal Zone B-Cell Lymphomas of Different Types. <i>American Journal of Clinical Pathology</i> , 2008, 129, 714-722.	0.8	40
736	Multiple Myeloma and Immunosecretory Disorders. <i>Advances in Anatomic Pathology</i> , 2008, 15, 196-210.	4.4	21
737	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. <i>Blood</i> , 2008, 111, 5530-5536.	1.4	296
738	Lymphomas Involving the Breast. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1299-1309.	4.0	160

#	ARTICLE	IF	CITATIONS
739	Expression of Helix-Loop-Helix Proteins in Classical Hodgkin Lymphoma: A Possible Explanation for a Characteristic Immunophenotype. <i>Advances in Anatomic Pathology</i> , 2008, 15, 97-104.	4.4	1
740	An Attractive Therapeutic Target, mTOR Pathway, in ALK+ Anaplastic Large Cell Lymphoma. <i>Advances in Anatomic Pathology</i> , 2008, 15, 105-112.	4.4	4
741	t(8;13)-positive Bilineal Lymphomas. <i>American Journal of Surgical Pathology</i> , 2008, 32, 14-20.	4.0	48
742	Addition of Rituximab to Mobilization and Conditioning Overcomes the Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) Score in Patients with Relapsed FL Undergoing Autologous Stem Cell Transplantation (AUTO).. <i>Blood</i> , 2008, 112, 1140-1140.	1.4	1
743	Pediatric Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia: The M. D. Anderson Cancer Center Experience. <i>Blood</i> , 2008, 112, 5068-5068.	1.4	0
744	Networking Modules of Canonical and Alternative NFκB Signaling in Growth and Survival Regulations of Large B Cell Lymphomas. <i>Blood</i> , 2008, 112, 3776-3776.	1.4	2
745	Hepatosplenic and Other $\hat{\text{I}}^{\beta 1}$ T-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2007, 127, 869-880.	0.8	136
746	Progress in T-Cell and NK-Cell Malignancies. <i>American Journal of Clinical Pathology</i> , 2007, 127, 494-495.	0.8	0
747	Mantle cell lymphoma with a rare involvement of the testicle. <i>Leukemia and Lymphoma</i> , 2007, 48, 1242-1243.	1.4	8
748	MALT Lymphoma Involving the Kidney. <i>American Journal of Clinical Pathology</i> , 2007, 128, 464-473.	0.8	37
749	High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. <i>Haematologica</i> , 2007, 92, 1297-1301.	3.5	88
750	Oral-Cutaneous CD4-Positive T-cell Lymphoma: A Study of Two Patients. <i>American Journal of Dermatopathology</i> , 2007, 29, 62-67.	0.7	14
751	c-Jun Expression and Activation are Restricted to CD30+ Lymphoproliferative Disorders. <i>American Journal of Surgical Pathology</i> , 2007, 31, 447-453.	4.0	43
752	Unusual expression of CD94 on CD8+ TCR- $\hat{\text{I}}^{\pm 2}$ T cells in infectious mononucleosis. <i>Annals of Diagnostic Pathology</i> , 2007, 11, 55-60.	1.4	0
753	Skin involvement in T-cell prolymphocytic leukemia. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 533-534.	1.3	14
754	Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. <i>Cancer</i> , 2007, 109, 77-83.	4.1	48
755	Systemic mastocytosis in association with chronic lymphocytic leukemia: A rare diagnosis. <i>Leukemia Research</i> , 2007, 31, 1755-1758.	1.1	10
756	Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma. <i>Modern Pathology</i> , 2007, 20, 1-7.	5.8	44

#	ARTICLE	IF	CITATIONS
757	HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. <i>Modern Pathology</i> , 2007, 20, 54-62.	5.8	37
758	Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping. <i>Modern Pathology</i> , 2007, 20, 811-820.	5.8	18
759	The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases. <i>British Journal of Haematology</i> , 2007, 136, 220-228.	2.8	56
760	Aberrant EVI1 expression in acute myeloid leukemias associated with the t(3;8)(q26;q24). <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 37-42.	1.0	24
761	Follicular Lymphoma in Staging Bone Marrow Specimens: Correlation of Histologic Findings With the Results of Flow Cytometry Immunophenotypic Analysis. <i>Archives of Pathology and Laboratory Medicine</i> , 2007, 131, 282-287.	2.6	28
762	CD20+ nodal marginal zone B-cell lymphoma with CD20 recurrence as an intracranial dural-based mass. <i>Leukemia and Lymphoma</i> , 2006, 47, 2253-2256.	1.4	4
763	Activation of Mammalian Target of Rapamycin Signaling Promotes Cell Cycle Progression and Protects Cells from Apoptosis in Mantle Cell Lymphoma. <i>American Journal of Pathology</i> , 2006, 169, 2171-2180.	4.2	109
764	Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. <i>Annals of Diagnostic Pathology</i> , 2006, 10, 263-268.	1.4	26
765	Metastatic tumors in bone marrow: histopathology and advances in the biology of the tumor cells and bone marrow environment. <i>Annals of Diagnostic Pathology</i> , 2006, 10, 169-192.	1.4	25
766	Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma. <i>Blood</i> , 2006, 107, 1240-1241.	1.4	10
767	c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma. <i>Blood</i> , 2006, 107, 2544-2547.	1.4	37
768	Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. <i>Blood</i> , 2006, 107, 4207-4213.	1.4	250
769	Current Problems With Staging Lymphomas Involving the Ovary. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1202-1203.	4.0	2
770	Immunohistochemical Analysis of CBFÎ²-SMMHC Protein Reveals a Unique Nuclear Localization in Acute Myeloid Leukemia With inv(16)(p13q22). <i>American Journal of Surgical Pathology</i> , 2006, 30, 1436-1444.	4.0	10
771	Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. <i>Modern Pathology</i> , 2006, 19, 25-33.	5.8	196
772	Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-Î²B activation. <i>Modern Pathology</i> , 2006, 19, 891-898.	5.8	17
773	MALT1 gene rearrangements and NF-Î²B activation involving p65 and p50 are absent or rare in primary MALT lymphomas of the breast. <i>Modern Pathology</i> , 2006, 19, 1402-1408.	5.8	34
774	Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma. <i>Leukemia Research</i> , 2006, 30, 497-501.	1.1	20

#	ARTICLE	IF	CITATIONS
775	Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. <i>European Journal of Haematology</i> , 2006, 77, 387-394.	2.3	37
776	The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. <i>Experimental Hematology</i> , 2006, 34, 1670-1679.	0.5	34
777	Translocation (3;8)(q26;q24): a recurrent chromosomal abnormality in myelodysplastic syndrome and acute myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2006, 166, 82-85.	1.0	23
778	Expression of Bcl-2 in gastrointestinal stromal tumors. <i>Cancer</i> , 2006, 106, 1617-1623.	4.1	37
779	Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. <i>Cancer</i> , 2006, 107, 1844-1851.	4.1	52
780	Activating FLT3 Mutations Are Detectable in Chronic and Blast Phases of Chronic Myeloproliferative Disorders Other Than Chronic Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2006, 126, 530-533.	0.8	59
781	Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups.. <i>Blood</i> , 2006, 108, 2742-2742.	1.4	9
782	Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).. <i>Blood</i> , 2006, 108, 2749-2749.	1.4	2
783	Massive Mobilization of AML Cells into Circulation by Disruption of Leukemia/Stroma Cell Interactions Using CXCR4 Antagonist AMD3100: First Evidence in Patients and Potential for Abolishing Bone Marrow Microenvironment-Mediated Resistance.. <i>Blood</i> , 2006, 108, 568-568.	1.4	15
784	Acute Myeloid Leukemia Associated with Variant t(8;21) Detected by Conventional Cytogenetic and Molecular Studies : A Report of Four Cases and Review of the Literature. <i>American Journal of Clinical Pathology</i> , 2006, 125, 267-272.	0.8	14
785	Myeloid Sarcoma Involving the Gynecologic Tract. <i>American Journal of Clinical Pathology</i> , 2006, 125, 783-790.	0.8	25
786	Expression of B Cell-Specific Activator Protein/PAX5 in Acute Myeloid Leukemia With t(8;21)(q22;q22). <i>American Journal of Clinical Pathology</i> , 2006, 126, 235-240.	0.8	14
787	Lymphomas Involving the Pleura: A Clinicopathologic Study of 34 Cases Diagnosed By Pleural Biopsy. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 1497-1502.	2.6	65
788	Nucleophosmin Gene Mutations in Acute Myeloid Leukemia. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 1687-1692.	2.6	40
789	Myeloid Sarcoma of the Urinary Bladder and Epididymis as a Primary Manifestation of Acute Myeloid Leukemia With inv(16). <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 862-866.	2.6	25
790	Nutlin-3A, an MDM2 Antagonist, Induces p53-Dependent Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma (HL).. <i>Blood</i> , 2006, 108, 2506-2506.	1.4	0
791	Overexpression of CXCR4 in Acute Myeloid Leukemia Predicts Adverse Overall and Progression-Free Survival Independently of FLT3 Gene Mutation.. <i>Blood</i> , 2006, 108, 1890-1890.	1.4	0
792	NPM-ALK Promotes Cell Cycle Progression through Activation of JNK and c-Jun in Anaplastic Large Cell Lymphoma.. <i>Blood</i> , 2006, 108, 2057-2057.	1.4	0

#	ARTICLE	IF	CITATIONS
793	Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia. <i>Advances in Anatomic Pathology</i> , 2005, 12, 246-255.	4.4	86
794	Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. <i>Blood</i> , 2005, 105, 827-829.	1.4	90
795	Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. <i>British Journal of Haematology</i> , 2005, 130, 726-728.	2.8	33
796	Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2005, 132, 051220022257008.	2.8	99
797	Combined laser capture microdissection and serial analysis of gene expression from human tissue samples. <i>Modern Pathology</i> , 2005, 18, 577-584.	5.8	18
798	JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. <i>Modern Pathology</i> , 2005, 18, 1365-1370.	5.8	69
799	Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. <i>Modern Pathology</i> , 2005, 18, 1343-1349.	5.8	40
800	Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 87-94.	3.4	10
801	Hodgkin Lymphoma Involving Waldeyer Ring. <i>American Journal of Clinical Pathology</i> , 2005, 123, 651-656.	0.8	49
802	Lymphoid Neoplasms Associated With IgM Paraprotein. <i>American Journal of Clinical Pathology</i> , 2005, 123, 200-205.	0.8	102
803	Biological Validation of Differentially Expressed Genes in Chronic Lymphocytic Leukemia Identified by Applying Multiple Statistical Methods to Oligonucleotide Microarrays. <i>Journal of Molecular Diagnostics</i> , 2005, 7, 337-345.	3.0	15
804	Body cavity-based presentation of natural killer cell lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 293-296.	1.4	15
805	Classical hodgkin lymphoma arising in the rectum. <i>Annals of Diagnostic Pathology</i> , 2005, 9, 38-42.	1.4	16
806	Langerhans cell histiocytosis presenting as a thyroid gland mass. <i>Annals of Diagnostic Pathology</i> , 2005, 9, 267-274.	1.4	20
807	Extranodal lymphomas of the head and neck. <i>Annals of Diagnostic Pathology</i> , 2005, 9, 340-350.	1.4	155
808	Inhibition of AKT/mTOR Signaling Induces Cell Cycle Arrest and Apoptosis in Mantle Cell Lymphoma.. <i>Blood</i> , 2005, 106, 2415-2415.	1.4	4
809	Immunophenotypic Profile of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia. <i>American Journal of Clinical Pathology</i> , 2005, 124, 414-420.	0.8	53
810	inv(16)(p13q22) in Chronic Myelogenous Leukemia in Blast Phase. <i>American Journal of Clinical Pathology</i> , 2005, 124, 807-814.	0.8	13

#	ARTICLE	IF	CITATIONS
811	Expression of bcl-3 in Chronic Lymphocytic Leukemia Correlates With Trisomy 12 and Abnormalities of Chromosome 19. American Journal of Clinical Pathology, 2005, 123, 465-471.	0.8	8
812	T-Cell Prolymphocytic Leukemia Involving Extramedullary Sites. American Journal of Clinical Pathology, 2005, 123, 456-464.	0.8	32
813	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Associated With IgM Paraprotein: A Clinicopathologic Study of 26 Cases. American Journal of Clinical Pathology, 2005, 123, 594-602.	0.8	15
814	Myeloid Sarcoma Involving the Testis. American Journal of Clinical Pathology, 2005, 124, 445-452.	0.8	14
815	Myeloid Sarcoma of Appendix Mimicking Acute Appendicitis. Archives of Pathology and Laboratory Medicine, 2005, 129, 1027-1031.	2.6	20
816	Myeloid Sarcoma Involving the Breast. Archives of Pathology and Laboratory Medicine, 2005, 129, 32-38.	2.6	59
817	Activation Status of the JAK/STAT3 Pathway in Mantle Cell Lymphoma. Archives of Pathology and Laboratory Medicine, 2005, 129, 990-996.	2.6	28
818	Heat Shock Protein 90 (HSP90) Inhibition by the Small Molecule 17-AAG Induces Cell Cycle Arrest and Apoptosis in Anaplastic Large Cell Lymphoma (ALCL) Irrespective of ALK Expression: Role of Akt, ERK and ALK Kinases in the Molecular Mechanisms of 17-AAG Anti-Tumor Activity.. Blood, 2005, 106, 2811-2811.	1.4	0
819	A Biologically Distinctive Subgroup of Acute Myelogenous Leukemia with Characteristic Nuclear Morphology and a High Frequency of FLT3 Mutation.. Blood, 2005, 106, 4522-4522.	1.4	0
820	Heat Shock Protein 90 (HSP90) Is Overexpressed in Primary and Cultured Hodgkin Lymphoma (HL) Cells: Role of Therapeutic Targeting Using the Small Molecule Inhibitor 17-AAG.. Blood, 2005, 106, 2422-2422.	1.4	0
821	Inhibition of AKT/mTOR Signaling Pathway Induces Cell Cycle Arrest and Apoptosis in Acute Myelogenous Leukemia.. Blood, 2005, 106, 2355-2355.	1.4	1
822	Differential Expression of the Homeobox Gene MIXL1 in Non Hodgkin (NHL) and Hodgkin Lymphomas (HL).. Blood, 2005, 106, 3014-3014.	1.4	0
823	Activation of mTOR Signaling Pathway Contributes to Tumoral Cell Survival in ALK-Positive Anaplastic Large Cell Lymphoma.. Blood, 2005, 106, 2419-2419.	1.4	0
824	cJun Is Phosphorylated at Ser73 and Contributes to Cell Cycle Progression in Anaplastic Large Cell Lymphoma.. Blood, 2005, 106, 2620-2620.	1.4	0
825	Peripheral T-Cell Lymphoma With a "Follicular" Pattern and the Perifollicular Sinus Phenotype. American Journal of Clinical Pathology, 2005, 123, 448-455.	0.8	6
826	Morphologic, Cytogenetic, and Molecular Abnormalities in Therapy-Related Acute Promyelocytic Leukemia. American Journal of Clinical Pathology, 2005, 123, 840-848.	0.8	10
827	Survivin Expression Predicts Poorer Prognosis in Anaplastic Large-Cell Lymphoma. Journal of Clinical Oncology, 2004, 22, 1682-1688.	5.3	155
828	Acute Myeloid Leukemia With t(6;9)(p23;q34) Is Associated With Dysplasia and a High Frequency of FLT3 Gene Mutations. American Journal of Clinical Pathology, 2004, 122, 348-358.	0.8	96

#	ARTICLE	IF	CITATIONS
829	Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma. <i>Leukemia</i> , 2004, 18, 1872-1878.	7.5	30
830	Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma. <i>Oncogene</i> , 2004, 23, 5426-5434.	5.9	148
831	Caspase-3 activation in systemic anaplastic large-cell lymphoma. <i>Modern Pathology</i> , 2004, 17, 109-116.	5.8	20
832	Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. <i>Modern Pathology</i> , 2004, 17, 911-917.	5.8	39
833	Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. <i>Modern Pathology</i> , 2004, 17, 946-953.	5.8	24
834	Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. <i>Modern Pathology</i> , 2004, 17, 954-961.	5.8	98
835	Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. <i>Cancer</i> , 2004, 101, 332-336.	4.1	66
836	Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin's Disease Treated with Radiotherapy. <i>Leukemia and Lymphoma</i> , 2004, 45, 2085-2092.	1.4	43
837	Isothermal Multiple Displacement Amplification. <i>Journal of Molecular Diagnostics</i> , 2004, 6, 236-242.	3.0	56
838	Quantitative PCR Detection of t(14;18) bcl-2/JH Fusion Sequences in Follicular Lymphoma Patients. <i>Journal of Molecular Diagnostics</i> , 2004, 6, 396-400.	3.0	11
839	Signal Transducer and Activator of Transcription-3 Activation Contributes to High Tissue Inhibitor of Metalloproteinase-1 Expression in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 164, 2251-2258.	4.2	21
840	Retinoblastoma Protein Is Frequently Absent or Phosphorylated in Anaplastic Large-Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 164, 2259-2267.	4.2	29
841	Absence of Epstein-Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria. <i>Human Pathology</i> , 2004, 35, 455-459.	2.4	60
842	Isolated Vulvar Langerhans Cell Histiocytosis: Report of Two Cases. <i>International Journal of Gynecological Pathology</i> , 2004, 23, 278-283.	1.6	27
843	The Role of the Perifollicular Sinus in Determining the Complex Immunoarchitecture of Angioimmunoblastic T-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1632-1640.	4.0	12
844	Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 489-495.	4.0	52
845	TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. <i>Modern Pathology</i> , 2004, 17, 96-103.	5.8	13
846	Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).. <i>Blood</i> , 2004, 104, 128-128.	1.4	10

#	ARTICLE	IF	CITATIONS
847	Acute Myeloid Leukemia With t(6;9)(p23;q34) Is Associated With Dysplasia and a High Frequency of flt3 Gene Mutations. <i>American Journal of Clinical Pathology</i> , 2004, 122, 348-358.	0.8	30
848	Expression of CD2 in Acute Promyelocytic Leukemia Correlates With Short Form of PML-RAR α Transcripts and Poorer Prognosis. <i>American Journal of Clinical Pathology</i> , 2004, 121, 402-407.	0.8	24
849	cDNA Microarray Analysis of Genes Associated with NPM-ALK Overexpression in Anaplastic Large Cell Lymphomas. <i>Blood</i> , 2004, 104, 2269-2269.	1.4	3
850	TCL1 Expression in B-Cell Tumors Is Dynamically Regulated by Maturation Stage, Proliferation, and the Follicular Microenvironment. <i>Blood</i> , 2004, 104, 4333-4333.	1.4	0
851	t(8;21)(q22;q22) in Blast Phase of Chronic Myelogenous Leukemia. <i>American Journal of Clinical Pathology</i> , 2004, 121, 836-842.	0.8	21
852	Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. <i>Cancer</i> , 2003, 97, 586-591.	4.1	236
853	A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. <i>Cancer</i> , 2003, 98, 310-314.	4.1	160
854	Improved detection of clonality in cutaneous T-cell lymphomas using laser capture microdissection. <i>Journal of Cutaneous Pathology</i> , 2003, 30, 486-491.	1.5	24
855	Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. <i>Oncogene</i> , 2003, 22, 5399-5407.	5.9	123
856	Phenotypic Modulation of the Stromal Reticular Network in Normal and Neoplastic Lymph Nodes. <i>American Journal of Pathology</i> , 2003, 163, 165-174.	4.2	50
857	Dysplasia and High Proliferation Rate Are Common in Acute Myeloid Leukemia With inv(16)(p13q22). <i>American Journal of Clinical Pathology</i> , 2003, 120, 236-245.	0.8	7
858	Diffuse Large B-Cell Lymphoma Occurring in Patients With Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia: Clinicopathologic Features of 12 Cases. <i>American Journal of Clinical Pathology</i> , 2003, 120, 246-253.	0.8	29
859	Waldenstrom Macroglobulinemia Involving Extramedullary Sites. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1104-1113.	4.0	71
860	Kikuchi-Fujimoto Lymphadenitis. <i>Advances in Anatomic Pathology</i> , 2003, 10, 204-211.	4.4	78
861	Dissolution of the Lymphoid Follicle Is a Feature of the HHV8+ Variant of Plasma Cell Castleman's Disease. <i>American Journal of Surgical Pathology</i> , 2003, 27, 91-100.	4.0	54
862	BCL-2 Is Consistently Expressed in Hyperplastic Marginal Zones of the Spleen, Abdominal Lymph Nodes, and Ileal Lymphoid Tissue. <i>American Journal of Surgical Pathology</i> , 2003, 27, 888-894.	4.0	22
863	Effects of Six Different Tissue Fixatives on DNA Quality as Determined by Polymerase Chain Reaction Amplification of Genes Ranging from 100 to 574 Base Pairs. <i>Journal of Histotechnology</i> , 2003, 26, 111-115.	0.7	2
864	TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. <i>Blood</i> , 2003, 101, 5007-5009.	1.4	184

#	ARTICLE	IF	CITATIONS
865	BCL-3 overexpression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. <i>Blood</i> , 2003, 102, 1146-1147.	1.4	24
866	c-kit is not expressed in Hodgkin disease and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma. <i>Blood</i> , 2003, 102, 4619-4620.	1.4	9
867	CD23 Expression in Mantle Cell Lymphoma: Clinicopathologic Features of 18 Cases. <i>American Journal of Clinical Pathology</i> , 2003, 120, 760-766.	0.8	19
868	Mature B-Cell Leukemias With More Than 55% Prolymphocytes. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 305-309.	2.6	30
869	Characterization of 4 Mantle Cell Lymphoma Cell Lines. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 424-431.	2.6	108
870	CD79b Expression in Chronic Lymphocytic Leukemia. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 561-566.	2.6	29
871	Molecular Monitoring of Cerebrospinal Fluid Can Predict Clinical Relapse in Acute Lymphoblastic Leukemia With Eosinophilia. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 601-605.	2.6	19
872	Chromosomal Translocations Involved in Non-Hodgkin Lymphomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 1148-1160.	2.6	71
873	Indolent Neuroendocrine Tumor Involving the Bone Marrow. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 488-491.	2.6	3
874	Apoptosis and Proliferation in Subcutaneous Panniculitis-Like T-Cell Lymphoma. <i>Modern Pathology</i> , 2002, 15, 625-631.	5.8	30
875	Precursor T-Cell Acute Lymphoblastic Leukemia in Adults. <i>American Journal of Clinical Pathology</i> , 2002, 117, 252-258.	0.8	16
876	Peripheral T-Cell Lymphoma Arising in the Liver. <i>American Journal of Clinical Pathology</i> , 2002, 118, 574-581.	0.8	25
877	Apoptotic Rate in Peripheral T-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2002, 118, 328-334.	0.8	58
878	Acute Lymphoblastic Leukemia in Elderly Patients. <i>American Journal of Clinical Pathology</i> , 2002, 117, 716-720.	0.8	9
879	Primary Cutaneous Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2002, 117, 574-580.	0.8	44
880	Discrepancies in the Immunophenotype of Lymphoma Cells in Samples Obtained Simultaneously From Different Anatomic Sites. <i>American Journal of Clinical Pathology</i> , 2002, 117, 644-650.	0.8	37
881	Quantitative Real-Time Polymerase Chain Reaction for Detection of Circulating Cells with T(14;18) in Volunteer Blood Donors and Patients with Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 1589-1598.	1.4	14
882	Malignant Fibrous Histiocytoma of the Spermatic Cord: Report of Two Cases and Review of the Literature. <i>Modern Pathology</i> , 2002, 15, 59-65.	5.8	19

#	ARTICLE	IF	CITATIONS
883	Real-Time t(14;18)(q32;q21) PCR Assay Combined with High-Resolution Capillary Electrophoresis: A Novel and Rapid Approach that Allows Accurate Quantitation and Size Determination of bcl-2/JH Fusion Sequences. <i>Modern Pathology</i> , 2002, 15, 448-453.	5.8	16
884	Real-Time RT-PCR Assay for Quantifying Cyclin D1 mRNA in B-Cell Non-Hodgkin's Lymphomas. <i>Modern Pathology</i> , 2002, 15, 556-564.	5.8	33
885	Clusterin Expression in Malignant Lymphomas: A Survey of 266 Cases. <i>Modern Pathology</i> , 2002, 15, 1221-1226.	5.8	67
886	Hypopigmented Mycosis Fungoides. <i>American Journal of Surgical Pathology</i> , 2002, 26, 450-457.	4.0	155
887	CD4 ⁺ CD8 ⁻ 'Double-Negative' Cutaneous T-Cell Lymphomas Share Common Histologic Features and an Aggressive Clinical Course. <i>American Journal of Surgical Pathology</i> , 2002, 26, 225-231.	4.0	63
888	Mantle Cell Lymphoma Involving Skin. <i>American Journal of Surgical Pathology</i> , 2002, 26, 1312-1318.	4.0	87
889	Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorders Arising in Immunodeficient Patients Previously Treated With Fludarabine for Low-Grade B-Cell Neoplasms. <i>American Journal of Surgical Pathology</i> , 2002, 26, 630-636.	4.0	91
890	BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. <i>Blood</i> , 2002, 100, 3935-3941.	1.4	91
891	Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. <i>Blood</i> , 2002, 100, 3369-3373.	1.4	133
892	Overexpression of Mcl-1 in Anaplastic Large Cell Lymphoma Cell Lines and Tumors. <i>American Journal of Pathology</i> , 2002, 160, 2309-2310.	4.2	42
893	Mantle Cell Lymphoma with 8q24 Chromosomal Abnormalities: a Report of 5 Cases with Blastoid Features. <i>Modern Pathology</i> , 2002, 15, 1266-1272.	5.8	108
894	Quantification of bcl-2/JH Fusion Sequences and a Control Gene by Multiplex Real-Time PCR Coupled with Automated Amplicon Sizing by Capillary Electrophoresis. <i>Journal of Molecular Diagnostics</i> , 2002, 4, 223-229.	3.0	17
895	Rapid Detection of IgH/BCL2 Rearrangement in Follicular Lymphoma by Interphase Fluorescence in Situ Hybridization with Bacterial Artificial Chromosome Probes. <i>Journal of Molecular Diagnostics</i> , 2002, 4, 144-149.	3.0	29
896	Determination of Cyclin D1 and CD20 mRNA Levels by Real-Time Quantitative RT-PCR from Archival Tissue Sections of Mantle Cell Lymphoma and Other Non-Hodgkin's Lymphomas. <i>Journal of Molecular Diagnostics</i> , 2002, 4, 201-208.	3.0	26
897	CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin's Disease: Associations With Presenting Features and Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2002, 20, 1278-1287.	5.3	79
898	Chromosomal translocations and their role in the pathogenesis of non-Hodgkin's lymphomas. <i>Pathology</i> , 2002, 34, 397-409.	0.7	8
899	International prognostic index-based outcomes for diffuse large B-cell lymphomas. <i>Cancer</i> , 2002, 94, 3083-3088.	4.1	47
900	The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B-cell tumours. <i>British Journal of Haematology</i> , 2002, 117, 569-576.	2.8	40

#	ARTICLE	IF	CITATIONS
901	CD56 TdT blastic natural killer cell tumor of the skin. <i>Cancer</i> , 2002, 94, 2401-2408.	4.1	5
902	Multiple Myeloma in Association With Sarcoidosis. <i>Archives of Pathology and Laboratory Medicine</i> , 2002, 126, 365-368.	2.6	22
903	Non-Hodgkin's Lymphoma Affecting the Testis: Is It Curable with Doxorubicin-Based Therapy?. <i>Clinical Lymphoma and Myeloma</i> , 2001, 2, 40-46.	2.3	43
904	Differential Expression of BCL-2 Family Proteins in ALK-Positive and ALK-Negative Anaplastic Large Cell Lymphoma of T/Null-Cell Lineage. <i>American Journal of Pathology</i> , 2001, 159, 527-535.	4.2	90
905	Hodgkin's Disease in Patients Infected with Human Immunodeficiency Virus: Frequency, Presentation and Clinical Outcome. <i>Leukemia and Lymphoma</i> , 2001, 41, 535-544.	1.4	14
906	Primary Cutaneous Non-Hodgkin's Lymphoma of Ann Arbor Stage I: Preferential Cutaneous Relapses but High Cure Rate With Doxorubicin-Based Therapy. <i>Journal of Clinical Oncology</i> , 2001, 19, 398-405.	5.3	33
907	Marginal-Zone B-Cell Lymphoma of Extranodal Mucosa-Associated Lymphoid Tissue Type: Molecular Genetics Provides New Insights into Pathogenesis. <i>Advances in Anatomic Pathology</i> , 2001, 8, 313-326.	4.4	22
908	Non-Hodgkin's Lymphoma Involving the Gynecologic Tract: A Review of 88 Cases. <i>Advances in Anatomic Pathology</i> , 2001, 8, 200-217.	4.4	98
909	Uterine Leiomyomas with Eosinophils: A Clinicopathologic Study of 3 Cases. <i>International Journal of Gynecological Pathology</i> , 2001, 20, 239-243.	1.6	16
910	Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy. <i>British Journal of Haematology</i> , 2001, 112, 776-782.	2.8	28
911	Localized non-Hodgkin lymphoma involving the thyroid gland. <i>Cancer</i> , 2001, 91, 629-635.	4.1	107
912	The T-Cell Chemokine Receptor CXCR3 Is Expressed Highly in Low-Grade Mycosis Fungoides. <i>American Journal of Clinical Pathology</i> , 2001, 115, 413-421.	0.8	82
913	A Novel Four-Color PCR Assay to Assess T-Cell Receptor Gamma Gene Rearrangements in Lymphoproliferative Lesions. <i>American Journal of Clinical Pathology</i> , 2001, 116, 17-24.	0.8	83
914	Cytogenetic Findings in Lymphoplasmacytic Lymphoma /Waldenström Macroglobulinemia. <i>American Journal of Clinical Pathology</i> , 2001, 116, 543-549.	0.8	126
915	Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Hodgkin Disease. <i>American Journal of Clinical Pathology</i> , 2001, 116, 34-40.	0.8	45
916	Hepatosplenic gamma/delta T-Cell Lymphoma in Bone Marrow. <i>American Journal of Clinical Pathology</i> , 2001, 116, 410-419.	0.8	107
917	Cytogenetic Findings in Mantle Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2001, 116, 886-892.	0.8	57
918	Mature B-Cell Leukemias With More Than 55% Prolymphocytes. <i>American Journal of Clinical Pathology</i> , 2001, 115, 571-581.	0.8	101

#	ARTICLE	IF	CITATIONS
919	Ovarian Non-Hodgkin's Lymphoma: A Clinicopathologic Study of Eight Primary Cases. <i>Modern Pathology</i> , 2001, 14, 1093-1099.	5.8	137
920	DNA Topoisomerase II± in Multiple Myeloma: A Marker of Cell Proliferation and Not Drug Resistance. <i>Modern Pathology</i> , 2001, 14, 886-891.	5.8	22
921	Anaplastic Lymphoma Kinase (ALK) is not Expressed in Hodgkin's Disease: Results with ALK-11 Antibody in 327 Untreated Patients. <i>Leukemia and Lymphoma</i> , 2001, 42, 969-979.	1.4	15
922	Reticulum Cell Sarcoma of Lymph Node with Mixed Dendritic and Fibroblastic Features. <i>Modern Pathology</i> , 2001, 14, 1059-1067.	5.8	53
923	Leukemic Mantle Cell Lymphoma: Clinical and Pathologic Spectrum of Twenty-Three Cases. <i>Modern Pathology</i> , 2001, 14, 1133-1140.	5.8	47
924	Localized non-Hodgkin lymphoma involving the thyroid gland. <i>Cancer</i> , 2001, 91, 629-635.	4.1	1
925	Cyclin D1 Expression in Dysplastic Nevi. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 208-210.	2.6	25
926	Posttransplantation Lymphoproliferative Disorders in Pediatric Patients Undergoing Liver Transplantation. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 337-343.	2.6	10
927	Pleural Posttransplantation Lymphoproliferative Disorder Following Liver Transplantation. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 419-423.	2.6	7
928	Primary Paratesticular Lymphoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 428-432.	2.6	21
929	Primary Follicular Large Cell Lymphoma of the Testis in a Child. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 551-554.	2.6	41
930	Neutrophil-Rich Anaplastic Large Cell Lymphoma of T-Cell Lineage. <i>American Journal of Clinical Pathology</i> , 2000, 114, 478-482.	0.8	63
931	Mucoepidermoid Carcinoma Involving Warthin Tumor. <i>American Journal of Clinical Pathology</i> , 2000, 114, 564-570.	0.8	63
932	Non-Hodgkin's Lymphoma Involving the Vulva. <i>International Journal of Gynecological Pathology</i> , 2000, 19, 236-242.	1.6	48
933	Endometrial Carcinoma and Non-Hodgkin's Lymphoma Involving the Female Genital Tract: A Report of Three Cases. <i>International Journal of Gynecological Pathology</i> , 2000, 19, 133-138.	1.6	18
934	Non-Hodgkin's Lymphoma Involving the Vagina. <i>American Journal of Surgical Pathology</i> , 2000, 24, 719-725.	4.0	50
935	Follicular Lymphoma with Monocytoid B-Cell Proliferation: Molecular Assessment of the Clonal Relationship between the Follicular and Monocytoid B-Cell Components. <i>Laboratory Investigation</i> , 2000, 80, 1593-1599.	4.0	21
936	5' 3' Exonuclease-Based Real-Time PCR Assays for Detecting the t(14;18)(q32;21): A Survey of 162 Malignant Lymphomas and Reactive Specimens. <i>Modern Pathology</i> , 2000, 13, 661-666.	5.8	35

#	ARTICLE	IF	CITATIONS
937	Progressive Multifocal Leukoencephalopathy with Concurrent Richter's Syndrome. <i>Leukemia and Lymphoma</i> , 2000, 38, 183-190.	1.4	18
938	Prognostic Implications Of Calbindin-D28k Expression in Lung Cancer: Analysis of 452 Cases. <i>Modern Pathology</i> , 2000, 13, 808-813.	5.8	10
939	Detection of Chromosome 11q13 Breakpoints by Interphase Fluorescence In Situ Hybridization. <i>American Journal of Clinical Pathology</i> , 2000, 114, 248-257.	0.8	46
940	Lymphohistiocytoid Mesothelioma. <i>American Journal of Clinical Pathology</i> , 2000, 113, 649-654.	0.8	60
941	B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Involving Bone Marrow With an Interfollicular Pattern. <i>American Journal of Clinical Pathology</i> , 2000, 114, 41-46.	0.8	16
942	Follicle Center Lymphoma and Warthin Tumor Involving the Same Anatomic Site. <i>American Journal of Clinical Pathology</i> , 2000, 113, 113-119.	0.8	49
943	Precursor B-cell Lymphoblastic Lymphoma. <i>American Journal of Surgical Pathology</i> , 2000, 24, 1480-1490.	4.0	205
944	Non-Hodgkin's Lymphomas Involving the Uterus: A Clinicopathologic Analysis of 26 Cases. <i>Modern Pathology</i> , 2000, 13, 19-28.	5.8	168
945	Sinusoidal CD30-Positive Large B-Cell Lymphoma: A Morphologic Mimic of Anaplastic Large Cell Lymphoma. <i>Modern Pathology</i> , 2000, 13, 223-228.	5.8	49
946	Sinus Histiocytosis with Massive Lymphadenopathy and Malignant Lymphoma Involving the Same Lymph Node: A Report of Four Cases and Review of the Literature. <i>Modern Pathology</i> , 2000, 13, 414-419.	5.8	110
947	Small Lymphocytic Lymphoma with Perifollicular, Marginal Zone, or Interfollicular Distribution. <i>Modern Pathology</i> , 2000, 13, 1161-1166.	5.8	31
948	Anaplastic Large Cell Lymphomas Presented as Bone Lesions: A Clinicopathologic Study of Six Cases and Review of the Literature. <i>Modern Pathology</i> , 2000, 13, 1143-1149.	5.8	47
949	Pathologic Diagnosis of Mantle Cell Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2000, 1, 197-206.	2.3	31
950	Pagetoid Bowen Disease. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 427-430.	2.6	70
951	Pathologic Quiz Case: A Unilateral Renal Mass in an Elderly Woman. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 919-920.	2.6	6
952	Anaplastic Large Cell Lymphoma Arising in Bone. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 1339-1343.	2.6	18
953	Natural Killer Cell Lymphoma Involving the Gynecologic Tract. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 1510-1513.	2.6	24
954	Acute Lymphoblastic Leukemia: Survey of Immunophenotype, French-American-British Classification, Frequency of Myeloid Antigen Expression, and Karyotypic Abnormalities in 210 Pediatric and Adult Cases. <i>American Journal of Clinical Pathology</i> , 1999, 111, 467-476.	0.8	101

#	ARTICLE	IF	CITATIONS
955	Intravascular Large B-Cell Lymphoma: A Report of Five Cases Initially Diagnosed by Bone Marrow Biopsy. <i>American Journal of Clinical Pathology</i> , 1999, 112, 248-255.	0.8	89
956	Real-Time 5' 3' Exonuclease-Based PCR Assay for Detection of the t(11;14)(q13;q32). <i>American Journal of Clinical Pathology</i> , 1999, 112, 524-530.	0.8	34
957	Primary Anaplastic Large Cell Lymphoma of the Small Intestine. <i>American Journal of Clinical Pathology</i> , 1999, 112, 696-701.	0.8	30
958	Cyclin D1 Overexpression in Spitz Nevi: An Immunohistochemical Study. <i>American Journal of Dermatopathology</i> , 1999, 21, 115-120.	0.7	60
959	Oncocytoid Renal Cell Carcinoma After Neuroblastoma: A Report of Four Cases of a Distinct Clinicopathologic Entity. <i>American Journal of Surgical Pathology</i> , 1999, 23, 772.	4.0	128
960	Overview of the Role of Molecular Methods in the Diagnosis of Malignant Lymphomas. <i>Archives of Pathology and Laboratory Medicine</i> , 1999, 123, 1189-1207.	2.6	96
961	Neurofibroma and Cellular Neurofibroma with Atypia: A report of 14 tumors. <i>American Journal of Surgical Pathology</i> , 1999, 23, 1156.	4.0	2
962	Surface Immunoglobulin Light Chain ⁺ Positive Acute Lymphoblastic Leukemia of FAB LI or L2 Type: A Report of 6 Cases in Adults. <i>American Journal of Clinical Pathology</i> , 1998, 110, 143-149.	0.8	36
963	The Immunophenotype of Adult Acute Myeloid Leukemia: High Frequency of Lymphoid Antigen Expression and Comparison of Immunophenotype, French-American-British Classification, and Karyotypic Abnormalities. <i>American Journal of Clinical Pathology</i> , 1998, 109, 211-220.	0.8	131
964	Hodgkin TM s Disease in Costa Rica: A Report of 40 Cases Analyzed for Epstein-Barr Virus. <i>American Journal of Clinical Pathology</i> , 1998, 109, 618-624.	0.8	19
965	Oncocytic Adrenocortical Neoplasms. <i>American Journal of Surgical Pathology</i> , 1998, 22, 603-614.	4.0	125
966	Presence of t(8;21)(q22;q22) in Myeloperoxidase-Positive, Myeloid Surface Antigen ⁺ Negative Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 1997, 107, 68-73.	0.8	29
967	Cyclin D1 Immunohistochemical Staining Is Useful in Distinguishing Mantle Cell Lymphoma From Other Low-Grade B-Cell Neoplasms in Bone Marrow. <i>American Journal of Clinical Pathology</i> , 1997, 108, 302-307.	0.8	94
968	Hodgkin TM s Disease of the Esophagus. <i>American Journal of Clinical Pathology</i> , 1997, 108, 593-598.	0.8	24
969	Detection of Epstein-Barr Virus in the L & H Cells of Nodular Lymphocyte Predominance Hodgkin TM s Disease: Report of a Case Documented by Immunohistochemical, In Situ Hybridization, and Polymerase Chain Reaction Methods. <i>American Journal of Clinical Pathology</i> , 1997, 108, 687-692.	0.8	21
970	Immunophenotype of Reed-Sternberg and Hodgkin TM s Cells in Sequential Biopsy Specimens of Hodgkin TM s Disease: A Paraffin-Section Immunohistochemical Study Using the Heat-Induced Epitope Retrieval Method. <i>American Journal of Clinical Pathology</i> , 1997, 108, 54-59.	0.8	29
971	The Heidelberg classification of renal cell tumours. <i>Journal of Pathology</i> , 1997, 183, 131-133.	4.5	1,176
972	Grading of renal cell carcinoma. <i>Cancer</i> , 1997, 80, 990-991.	4.1	87

#	ARTICLE	IF	CITATIONS
973	Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. <i>Cancer</i> , 1997, 80, 1768-1775.	4.1	77
974	The Heidelberg classification of renal cell tumours. <i>Journal of Pathology</i> , 1997, 183, 131.	4.5	8
975	The Heidelberg classification of renal cell tumours. <i>Journal of Pathology</i> , 1997, 183, 131-133.	4.5	62
976	Transformation of Follicular Lymphoma into CD30-Large Cell Lymphoma with Anaplastic Cytologic Features. <i>American Journal of Surgical Pathology</i> , 1997, 21, 528-536.	4.0	43
977	Neurofibroma and Cellular Neurofibroma With Atypia. <i>American Journal of Surgical Pathology</i> , 1997, 21, 1443-1449.	4.0	81
978	Splenic Marginal Zone Cell Lymphoma: An Immunophenotypic and Molecular Study of Five Cases. <i>American Journal of Clinical Pathology</i> , 1996, 105, 277-285.	0.8	38
979	Gastric Lymphoepithelioma-like Carcinoma and Jejunal B-Cell MALT Lymphoma With Large Cell Transformation: Demonstration of EBV With Identical LMP Gene Deletions in the Carcinoma and Large Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 1996, 105, 560-566.	0.8	14
980	p53 Expression in Reed-Sternberg Cells Does Not Correlate With Gene Mutations in Hodgkin's Disease. <i>American Journal of Clinical Pathology</i> , 1996, 106, 728-738.	0.8	43
981	Transthyretin (Prealbumin) Immunoreactivity in Renal Cell Carcinoma and Other Neoplasms. <i>International Journal of Surgical Pathology</i> , 1996, 4, 1-7.	0.9	5
982	Chronic Myeloid Leukemia Manifested During Megakaryoblastic Crisis. <i>Southern Medical Journal</i> , 1996, 89, 422-427.	0.7	13
983	Thrombotic Thrombocytopenic Purpura and HIV Infection. <i>Southern Medical Journal</i> , 1995, 88, 82-86.	0.7	18
984	B-Cell Chronic Lymphocytic Leukemia Followed by High Grade T-Cell Lymphoma: An Unusual Variant of Richter's Syndrome. <i>American Journal of Clinical Pathology</i> , 1995, 103, 348-352.	0.8	51
985	Plasma Cell Myeloma Associated With Eosinophilia. <i>American Journal of Clinical Pathology</i> , 1995, 103, 583-587.	0.8	14
986	Adult Renal Epithelial Neoplasms. <i>American Journal of Clinical Pathology</i> , 1995, 103, 624-635.	0.8	132
987	Adrenal Cortical Tumors Clinically Mimicking Pheochromocytoma. <i>American Journal of Clinical Pathology</i> , 1995, 104, 382-390.	0.8	51
988	Lymphoma of the Mucosa-Associated Lymphoid Tissue of the Lung: A Multifocal Case of Common Clonal Origin. <i>American Journal of Clinical Pathology</i> , 1995, 103, 341-345.	0.8	14
989	Epstein-Barr Virus Is Infrequently Identified in Non-Hodgkin's Lymphomas Associated with Hodgkin's Disease. <i>American Journal of Surgical Pathology</i> , 1994, 18, 48-61.	4.0	86
990	Malignant Lymphomas of B-Cell Lineage with Marked Tissue Eosinophilia. <i>American Journal of Surgical Pathology</i> , 1994, 18, 347-356.	4.0	36

#	ARTICLE	IF	CITATIONS
991	bcl-2 Rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features. <i>Cancer</i> , 1993, 72, 231-236.	4.1	99
992	Stage I Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 1993, 17, 275-286.	4.0	87
993	Malignant Lymphomas Involving the Ovary. <i>American Journal of Surgical Pathology</i> , 1993, 17, 154-170.	4.0	173
994	bcl-2 Expression in Hodgkin's Disease: Correlation with the t(14; 18) Translocation and Epstein-Barr Virus. <i>American Journal of Clinical Pathology</i> , 1993, 99, 604-608.	0.8	40
995	T-Cell Lymphoblastic Lymphoma With Eosinophilia Associated With Subsequent Myeloid Malignancy. <i>American Journal of Surgical Pathology</i> , 1992, 16, 236-245.	4.0	114
996	New Developments in the Pathologic Diagnosis of Adrenal Cortical Neoplasms: A Review. <i>American Journal of Clinical Pathology</i> , 1992, 97, 73-83.	0.8	116
997	Composite B-Cell and T-Cell Lymphoma: Coincidental Occurrence or Related Neoplasms? <i>American Journal of Clinical Pathology</i> , 1992, 98, 387-389.	0.8	27
998	Diffuse Aggressive B-Cell Lymphomas of the Gastrointestinal Tract: An Immunophenotypic and Gene Rearrangement Analysis of 22 Cases. <i>American Journal of Clinical Pathology</i> , 1992, 97, 170-178.	0.8	16
999	Mediastinal Lymphoblastic Lymphoma With an Immature B-Cell Immunophenotype. <i>American Journal of Surgical Pathology</i> , 1992, 16, 300-305.	4.0	34
1000	Lymphoproliferative Lesions in Patients with Common Variable Immunodeficiency Syndrome. <i>American Journal of Surgical Pathology</i> , 1992, 16, 1170-1182.	4.0	124
1001	Localization of Epstein-Barr Viral Genomes in Angiocentric Immunoproliferative Lesions. <i>American Journal of Surgical Pathology</i> , 1992, 16, 439-447.	4.0	145
1002	Non-Hodgkin's Lymphomas Arising in Patients Successfully Treated for Hodgkin's Disease. <i>American Journal of Surgical Pathology</i> , 1992, 16, 885-895.	4.0	61
1003	Lymphoblastic lymphoma presenting in cutaneous sites. <i>Journal of the American Academy of Dermatology</i> , 1991, 25, 1023-1031.	1.3	113
1004	My 4 Antibody Staining of Non-Hodgkin's Lymphomas. <i>American Journal of Clinical Pathology</i> , 1991, 95, 363-368.	0.8	24
1005	Genotypic Analysis of Diffuse, Mixed Cell Lymphomas: Comparisons with Morphologic and Immunophenotypic Findings. <i>American Journal of Clinical Pathology</i> , 1991, 95, 547-555.	0.8	18
1006	T-Cell-Rich B-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 1991, 15, 491.	4.0	14
1007	T-Cell Lymphoma Involving Subcutaneous Tissue. <i>American Journal of Surgical Pathology</i> , 1991, 15, 17-27.	4.0	442
1008	Cellular DNA Profiles of Benign and Malignant Adrenocortical Tumors. <i>American Journal of Surgical Pathology</i> , 1990, 14, 948-955.	4.0	57

#	ARTICLE	IF	CITATIONS
1009	Expression of the activation antigen, 4F2, by non-Hodgkin's lymphomas of B-cell phenotype. <i>Cancer</i> , 1990, 66, 1158-1164.	4.1	7
1010	Expression of LFA-1 in non-hodgkin's lymphoma. <i>Cancer</i> , 1989, 63, 255-259.	4.1	54
1011	Immunophenotypic Diagnosis of Non-Hodgkin's Lymphoma in Paraffin Sections: Co-Expression of L60 (Leu-22) and L26 Antigens Correlates with Malignant Histologic Findings. <i>American Journal of Clinical Pathology</i> , 1989, 91, 579-583.	0.8	72
1012	Pathologic Features of Prognostic Significance in Adrenocortical Carcinoma. <i>American Journal of Surgical Pathology</i> , 1989, 13, 202-206.	4.0	746
1013	Lymphoid Infiltrates of the Orbit and Conjunctiva. <i>American Journal of Surgical Pathology</i> , 1989, 13, 459-471.	4.0	125
1014	Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. <i>Cancer</i> , 1988, 61, 1639-1651.	4.1	224
1015	Transferrin receptor expression by non-hodgkin's lymphomas. Correlation with morphologic grade and survival. <i>Cancer</i> , 1988, 61, 1844-1851.	4.1	31
1016	Utility of combining antigranulocyte with antileukocyte antibodies in differentiating Hodgkin's disease from non-Hodgkin's lymphoma. <i>Cancer</i> , 1988, 62, 2475-2481.	4.1	22
1017	The Cells of Giant Cell Tumor of Tendon Sheath Resemble Osteoclasts. <i>American Journal of Surgical Pathology</i> , 1988, 12, 444-452.	4.0	47
1018	The Diagnostic Utility of the Keratin Profiles of Hepatocellular Carcinoma and Cholangiocarcinoma. <i>American Journal of Surgical Pathology</i> , 1988, 12, 187-197.	4.0	120
1019	Case 38-1988. <i>New England Journal of Medicine</i> , 1988, 319, 768-781.	30.7	21
1020	Reliability and Significance of Increased Creatine Kinase MB Isoenzyme in the Serum of Uremic Patients. <i>American Journal of Clinical Pathology</i> , 1987, 87, 103-108.	0.8	20
1021	The White Blood Cell Differential: Evaluation of Rapid Impression Scanning Versus the Routine Manual Count. <i>American Journal of Clinical Pathology</i> , 1987, 87, 628-632.	0.8	5
1022	Expression of Tac Antigen by Non-Hodgkin's Lymphomas. <i>American Journal of Clinical Pathology</i> , 1987, 88, 483-485.	0.8	14
1023	Low-Grade Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 1987, 11, 633-642.	4.0	31
1024	Age and Erythrocyte Alloimmunization. <i>Vox Sanguinis</i> , 1986, 51, 73-73.	1.6	7
1025	PRIMARY NODULAR LYMPHOMA OF THE LUNG Immunoperoxidase and Ultrastructural Studies. <i>Pathology International</i> , 1982, 32, 835-842.	1.4	0
1026	Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. <i>Modern Pathology</i> , 0, , .	5.8	1

#	ARTICLE	IF	CITATIONS
1027	Myeloid neoplasm with $\leq 10\%$ blasts and $t(3;5)(q25.1;q34)/i(NPM::MLF1)</i>$: A classification dilemma. American Journal of Hematology, 0, , .	4.3	2